Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
15 "dementia"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Brief communication
Evaluating the validity and reliability of the Korean version of Scales for Outcomes in Parkinson’s Disease–Cognition
Jinse Park, Eung Seok Oh, Seong-Beom Koh, In-Uk Song, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Yun Joong Kim, Jin Whan Cho, Hyeo-Il Ma, Mee-Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeok Lee, Jee-Young Lee, Ji Sun Kim, Ji Young Yun, Hee Jin Kim, Jin Young Hong, Mi-Jung Kim, Jinyoung Youn, Ji Seon Kim, Hui-Jun Yang, Won Tae Yoon, Sooyeoun You, Kyum-Yil Kwon, Su-Yun Lee, Younsoo Kim, Hee-Tae Kim, Joong-Seok Kim, Ji-Young Kim
Received March 8, 2024  Accepted April 2, 2024  Published online April 3, 2024  
DOI: https://doi.org/10.14802/jmd.24061    [Accepted]
  • 440 View
  • 19 Download
AbstractAbstract PDF
Objective
The Scales for Outcomes in Parkinson’s Disease–Cognition (SCOPA-Cog) was developed to screen for cognition in PD. In this study, we aimed to evaluate the validity and reliability of the Korean version of the SCOPA-cog.
Methods
We recruited 129 PD patients from 31 clinics with movement disorders in South Korea. The original version of the SCOPA-cognition was translated into Korean using the translation-retranslation method. The test-rest method with an intraclass correlation coefficient (ICC) and Cronbach’s alpha coefficient were used to assess reliability. The Spearman’s Rank correlation analysis with Montreal Cognitive Assessment-Korean version (MOCA-K) and Korean Mini-Mental State Examination (K-MMSE) were used to assess concurrent validity.
Results
The Cronbach’s alpha coefficient was 0.797, and the ICC was 0.887. Spearman’s rank correlation analysis showed a significant correlation with the K-MMSE and MOCA-K scores (r = 0.546 and r = 0.683, respectively).
Conclusions
Our results demonstrate that K-SCOPA-Cog exhibits good reliability and validity.
Original Article
Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease
Han Soo Yoo, Seok Jong Chung, Yang Hyun Lee, Byoung Seok Ye, Young H. Sohn, Phil Hyu Lee
J Mov Disord. 2020;13(2):133-141.   Published online April 6, 2020
DOI: https://doi.org/10.14802/jmd.19082
  • 10,142 View
  • 282 Download
  • 21 Web of Science
  • 21 Crossref
AbstractAbstract PDFSupplementary Material
Objective
To investigate whether baseline olfactory dysfunction in Parkinson’s disease (PD) patients is associated with baseline and longitudinal motor and cognitive function.
Methods
We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9), hyposmia (CCSIT score 5–8), and anosmia (CCSIT score ≤ 4). During the follow-up period, we investigated changes in the levodopa-equivalent dose (LED) and the occurrence of wearing-off, levodopa-induced dyskinesia, and dementia.
Results
Among the PD patients, 80.7% were hyposmic at the time of diagnosis, and 26.1% were anosmic. Baseline olfactory dysfunction was not associated with either initial parkinsonian motor symptoms or with the longitudinal LED increment and motor complications. Meanwhile, the anosmic group had lower baseline scores on the Korea version of the Boston Naming Test and Stroop color reading test than the normosmic and hyposmic groups. The anosmic group exhibited a higher rate of conversion to dementia than the normosmic [adjusted hazard ratio (HR) 3.99, 95% confidence interval (CI) 1.08–14.72] and hyposmic (adjusted HR 2.48, 95% CI 1.15–5.32) PD groups, regardless of baseline motor deficits and cognitive status.
Conclusion
Baseline olfactory dysfunction was not associated with motor deficits and complications, but it was associated with cognitive dysfunction and prognosis, suggesting that severe olfactory impairment may reflect early cortical involvement, probably in the frontotemporal region, and rapid spreading of Lewy body pathology.

Citations

Citations to this article as recorded by  
  • Correlation of olfactory function factors with cardiac sympathetic denervation in Parkinson’s disease
    Dong-Woo Ryu, Sang-Won Yoo, Ko-Eun Choi, Yoon-Sang Oh, Joong-Seok Kim
    Journal of Neurology.2024; 271(3): 1397.     CrossRef
  • Estimating motor progression trajectory pursuant to temporal dynamic status of cardiac denervation in Parkinson’s disease
    Sang-Won Yoo, Dong-Woo Ryu, Yoon-Sang Oh, Seunggyun Ha, Chul Hyoung Lyoo, Yuna Kim, Ji-Yeon Yoo, Joong-Seok Kim
    Journal of Neurology.2024; 271(4): 2019.     CrossRef
  • Olfactory Dysfunction in Parkinson’s Disease, Its Functional and Neuroanatomical Correlates
    Gabriel Torres-Pasillas, Donají Chi-Castañeda, Porfirio Carrillo-Castilla, Gerardo Marín, María Elena Hernández-Aguilar, Gonzalo Emiliano Aranda-Abreu, Jorge Manzo, Luis I. García
    NeuroSci.2023; 4(2): 134.     CrossRef
  • Impact of deep brain stimulation (DBS) on olfaction in Parkinson's disease: Clinical features and functional hypotheses
    G. Brand, C. Bontempi, L. Jacquot
    Revue Neurologique.2023; 179(9): 947.     CrossRef
  • Sequential change in olfaction and (non) motor symptoms: the difference between anosmia and non-anosmia in Parkinson’s disease
    Ting-Chun Fang, Yu-Shan Tsai, Ming-Hong Chang
    Frontiers in Aging Neuroscience.2023;[Epub]     CrossRef
  • Traumatic brain injury-induced inflammatory changes in the olfactory bulb disrupt neuronal networks leading to olfactory dysfunction
    Xiang Liu, Zhuofan Lei, Dylan Gilhooly, Junyun He, Yun Li, Rodney M. Ritzel, Hui Li, Long-Jun Wu, Shaolin Liu, Junfang Wu
    Brain, Behavior, and Immunity.2023; 114: 22.     CrossRef
  • Serum Biomarkers of Olfactory Identification Deficits in Patients with Parkinson’s Disease
    Fu-Jia Li, Yang-Dan-Yu Li, Xu Liu, Jie Zu, Wei Zhang, Qi-Hua Xiao, Xue-Bin Niu, Li Du, Chen-Chen Cui, Ru-Yu Zhang, Xiao-Qing He, Gui-Yun Cui, Chuan-Ying Xu, Dominic B. Fee
    Acta Neurologica Scandinavica.2023; 2023: 1.     CrossRef
  • UPSIT subitems may predict motor progression in Parkinson’s disease
    Yu-Hsuan Lin, Ting-Chun Fang, Hsin-Bei Lei, Shih-Chi Chiu, Ming-Hong Chang, Yi-Jen Guo
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease
    Fardin Nabizadeh, Kasra Pirahesh, Elham Khalili
    Neurological Sciences.2022; 43(7): 4193.     CrossRef
  • Novel diagnostic tools for identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy: patient-level, single-group, diagnostic trial
    Jaewon Kim, Dong Keon Yon, Kyu Yeong Choi, Jang Jae Lee, Namwoo Kim, Kun Ho Lee, Jae Gwan Kim
    Alzheimer's Research & Therapy.2022;[Epub]     CrossRef
  • The Role of Olfactory System in the Etiogenesis of Parkinson’s Diseases: An Overview
    Jiju Narayanan Avanipully, Dithu Thekkekkara, Sahyadri M, Vipan K. Parihar, Santhepete Nanjundaiah Manjula
    Journal of Pharmacology and Pharmacotherapeutics.2022; 13(1): 31.     CrossRef
  • International consensus statement on allergy and rhinology: Olfaction
    Zara M. Patel, Eric H. Holbrook, Justin H. Turner, Nithin D. Adappa, Mark W. Albers, Aytug Altundag, Simone Appenzeller, Richard M. Costanzo, Ilona Croy, Greg E. Davis, Puya Dehgani‐Mobaraki, Richard L. Doty, Valerie B. Duffy, Bradley J. Goldstein, David
    International Forum of Allergy & Rhinology.2022; 12(4): 327.     CrossRef
  • Does Olfactory Dysfunction Correlate with Disease Progression in Parkinson’s Disease? A Systematic Review of the Current Literature
    Tommaso Ercoli, Carla Masala, Gianluca Cadeddu, Marcello Mario Mascia, Gianni Orofino, Angelo Fabio Gigante, Paolo Solla, Giovanni Defazio, Lorenzo Rocchi
    Brain Sciences.2022; 12(5): 513.     CrossRef
  • Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease
    Fardin Nabizadeh, Fatemeh Sodeifian, Kasra Pirahesh
    Neurological Sciences.2022; 43(8): 4745.     CrossRef
  • Olfaction and Executive Cognitive Performance: A Systematic Review
    Vasudeva Murthy Challakere Ramaswamy, Peter William Schofield
    Frontiers in Psychology.2022;[Epub]     CrossRef
  • Nasal and Parotid Blood Pool Activity Is Significantly Correlated with Metabolic Syndrome Components and Sleep Apnea
    William T. Phillips, Nasser J. Issa, Shereef B. Elhalwagi, Hilda T. Draeger, Joyce G. Schwartz, Jonathan A. Gelfond
    Metabolic Syndrome and Related Disorders.2022; 20(7): 395.     CrossRef
  • Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium
    Gabriel A. de Erausquin, Heather Snyder, Traolach S. Brugha, Sudha Seshadri, Maria Carrillo, Rajesh Sagar, Yueqin Huang, Charles Newton, Carmela Tartaglia, Charlotte Teunissen, Krister Håkanson, Rufus Akinyemi, Kameshwar Prasad, Giovanni D'Avossa, Gabriel
    Alzheimer's & Dementia: Translational Research & Clinical Interventions.2022;[Epub]     CrossRef
  • Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease
    Joshua Harvey, Rick A. Reijnders, Rachel Cavill, Annelien Duits, Sebastian Köhler, Lars Eijssen, Bart P. F. Rutten, Gemma Shireby, Ali Torkamani, Byron Creese, Albert F. G. Leentjens, Katie Lunnon, Ehsan Pishva
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Impact of Subthalamic Deep Brain Stimulation on Hyposmia in Patients With Parkinson's Disease Is Influenced by Constipation and Dysbiosis of Microbiota
    Chao Li, Ying Hou, Xu Wang, Yue-xuan Li, Feng Li, Chao Zhang, Wei-guo Li
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Hyposmia may predict development of freezing of gait in Parkinson’s disease
    Jae Jung Lee, Jin Yong Hong, Jong Sam Baik
    Journal of Neural Transmission.2021; 128(6): 763.     CrossRef
  • Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson’s Disease
    Han Soo Yoo, Sangwon Lee, Seong Ho Jeong, Byoung Seok Ye, Young H. Sohn, Mijin Yun, Phil Hyu Lee
    Journal of Parkinson's Disease.2021; 11(4): 1703.     CrossRef
Review Article
Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions
Masahito Yamada, Junji Komatsu, Keiko Nakamura, Kenji Sakai, Miharu Samuraki-Yokohama, Kenichi Nakajima, Mitsuhiro Yoshita
J Mov Disord. 2020;13(1):1-10.   Published online November 8, 2019
DOI: https://doi.org/10.14802/jmd.19052
  • 26,265 View
  • 1,702 Download
  • 42 Web of Science
  • 48 Crossref
AbstractAbstract PDF
The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria. The criteria for the clinical diagnosis of probable and possible DLB were first published as the first consensus report in 1996 and were revised in the third consensus report in 2005. After discussion at the International DLB Conference in Fort Lauderdale, Florida, USA, in 2015, the International DLB Consortium published the fourth consensus report including the revised consensus criteria in 2017. The 2017 revised criteria clearly distinguish between clinical features and diagnostic biomarkers. Significant new information about previously reported aspects of DLB has been incorporated, with increased diagnostic weighting given to rapid eye movement (REM) sleep behavior disorder (RBD) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. Future directions include the development of the criteria for early diagnosis (prodromal DLB) and the establishment of new biomarkers that directly indicate Lewy-related pathology, including α-synuclein imaging, biopsies of peripheral tissues (skin, etc.) for the demonstration of α-synuclein deposition, and biochemical markers (cerebrospinal fluid/blood), as well as the pathological evaluation of the sensitivity and specificity of the 2017 revised diagnostic criteria. In conclusion, the revised consensus criteria for the clinical diagnosis of DLB were reported with the incorporation of new information about DLB in 2017. Future directions include the development of the criteria for early diagnosis and the establishment of biomarkers directly indicative of Lewy-related pathology.

Citations

Citations to this article as recorded by  
  • The Role of Electroconvulsive Therapy in the Treatment of Catatonia Associated With Lewy Body Dementia: A Case Report
    Javeria Sahib Din, Thomas Boes, Ernesto Navarro Garcia, Hiba Al-Rubaye
    Cureus.2024;[Epub]     CrossRef
  • α-Synuclein pathology from the body to the brain: so many seeds so close to the central soil
    Yunying Yang, Zhentao Zhang
    Neural Regeneration Research.2024; 19(7): 1463.     CrossRef
  • Suspecting Non-Alzheimer’s Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images
    Vincent Malotaux, Lise Colmant, Lisa Quenon, Lara Huyghe, Thomas Gérard, Laurence Dricot, Adrian Ivanoiu, Renaud Lhommel, Bernard Hanseeuw
    Journal of Alzheimer's Disease.2024; 97(1): 421.     CrossRef
  • Supercomplex formation of mitochondrial respiratory chain complexes in leukocytes from patients with neurodegenerative diseases
    Tsukasa Hara, Ryosuke Amagai, Ryuji Sakakibara, Ayako Okado-Matsumoto
    The Journal of Biochemistry.2024; 175(3): 289.     CrossRef
  • Latest advances in mechanisms of epileptic activity in Alzheimer’s disease and dementia with Lewy Bodies
    Mariane Vicente, Kwaku Addo-Osafo, Keith Vossel
    Frontiers in Neurology.2024;[Epub]     CrossRef
  • The clinical diagnosis of Parkinson's disease
    Renato P. Munhoz, Vitor Tumas, José Luiz Pedroso, Laura Silveira-Moriyama
    Arquivos de Neuro-Psiquiatria.2024; 82(06): 001.     CrossRef
  • Identification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach
    Megha Manoj, Siddarth Sowmyanarayan, Arjun V. Kowshik, Jhinuk Chatterjee
    Journal of Molecular Neuroscience.2024;[Epub]     CrossRef
  • Altered structural and functional connectivity in Posterior Cortical Atrophy and Dementia with Lewy bodies
    Neha Atulkumar Singh, Austin W. Goodrich, Jonathan Graff-Radford, Mary M. Machulda, Irene Sintini, Arenn F. Carlos, Carling G. Robinson, Robert I. Reid, Val J. Lowe, Clifford R. Jack, Ronald C. Petersen, Bradley F. Boeve, Keith A. Josephs, Kejal Kantarci,
    NeuroImage.2024; 290: 120564.     CrossRef
  • Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort
    Niyatee Samudra, D. Luke Fischer, Steven Lenio, Argentina Lario Lago, Peter A. Ljubenkov, Julio C. Rojas, William W. Seeley, Salvatore Spina, Adam M. Staffaroni, Jonathan Tablante, Fattin Wekselman, Jennifer Lamoureux, Luis Concha‐Marambio, Lea T. Grinber
    Alzheimer's & Dementia.2024; 20(5): 3334.     CrossRef
  • New insight of exercise on dementia; combinatory effects of physical and cognitive exercise
    Hyo-Jeong Cha, Jun Hong Park, Changwan Hong
    Molecular & Cellular Toxicology.2024;[Epub]     CrossRef
  • Magnetic resonance imaging in the diagnosis of progressive supranuclear palsy: A case report and review of literature
    Baraka Alphonce, Francisca Komanya, Mbelwa Bitesigilwe, John R. Meda, Azan Nyundo
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes
    Jun Yang, Ayotimofe Idowu, Liana Rosenthal, Xiaobo Mao
    Clinical and Translational Discovery.2023;[Epub]     CrossRef
  • Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia
    Irene Frigerio, Max A. Laansma, Chen-Pei Lin, Emma J. M. Hermans, Maud M. A. Bouwman, John G. J. M. Bol, Yvon Galis-de Graaf, Dagmar H. Hepp, Annemieke J. M. Rozemuller, Frederik Barkhof, Wilma D. J. van de Berg, Laura E. Jonkman
    Translational Neurodegeneration.2023;[Epub]     CrossRef
  • Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio
    Koichi Okuda, Kenichi Nakajima, Chiemi Kitamura, Michael Ljungberg, Tetsuo Hosoya, Yumiko Kirihara, Mitsumasa Hashimoto
    Journal of Nuclear Cardiology.2023; 30(4): 1630.     CrossRef
  • Costs During the Last Five Years of Life for Patients with Clinical and Pathological Confirmed Diagnosis of Lewy Body Dementia and Alzheimer’s Disease
    Carolyn W. Zhu, Yian Gu, Anton J. Kociolek, Kayri K. Fernandez, Stephanie Cosentino, Yaakov Stern
    Journal of Alzheimer's Disease.2023; 92(2): 457.     CrossRef
  • Early- and late-onset of isolated rapid eye movement sleep behavior disorder: A retrospective cohort study
    Li Zhou, Bei Huang, Jing Wang, Steven WH. Chau, Joey WY. Chan, Jihui Zhang, Mandy WM. Yu, Jessie CC. Tsang, Shirley Xin Li, Vincent CT. Mok, Yun Kwok Wing, Yaping Liu
    Sleep Medicine.2023;[Epub]     CrossRef
  • Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions
    Oliver Phillips, Debolina Ghosh, Hubert H. Fernandez
    Current Treatment Options in Neurology.2023; 25(5): 93.     CrossRef
  • Rapidly progressive dementia with severe insomnia: an unusual case of progressive supranuclear palsy mimicking dementia with Lewy bodies
    Rae On Kim, Eun Ji Lee, Seong-Ik Kim, Sung-Hye Park, Kyum-Yil Kwon
    Neurological Sciences.2023; 44(8): 2953.     CrossRef
  • Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
    Nils Schröter, Thilo van Eimeren, Joseph Classen, Johannes Levin, Christoph Redecker, Martin Wolz, Lars Tönges
    Journal of Neural Transmission.2023; 130(6): 839.     CrossRef
  • Electroencephalography in young onset dementia
    Casey W Brown, Huei-Yang Chen, Peter K Panegyres
    BMC Neurology.2023;[Epub]     CrossRef
  • Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers
    Lucy L. Gibson, Carla Abdelnour, Joyce Chong, Clive Ballard, Dag Aarsland
    Current Opinion in Neurology.2023; 36(4): 264.     CrossRef
  • Coexistence of Posterior Cortical Atrophy and Parkinson’s Disease
    Eun-Byul Ko, Il-Joong Hwang, Jung-Woo Kim, Dar-Eun Jung, Ju-Suk Lee, Sang-Won Yoo, Joong-Seok Kim
    Journal of the Korean Neurological Association.2023; 41(3): 216.     CrossRef
  • Toward a new nosology of neurodegenerative diseases
    Manuel Menéndez‐González
    Alzheimer's & Dementia.2023; 19(8): 3731.     CrossRef
  • Autonomic dysfunction in dementia with Lewy bodies: Focusing on cardiovascular and respiratory dysfunction
    Katsuyoshi Mizukami
    Psychiatry and Clinical Neurosciences Reports.2023;[Epub]     CrossRef
  • Beyond Strains: Molecular Diversity in Alpha-Synuclein at the Center of Disease Heterogeneity
    Marcelina J. Wojewska, Maria Otero-Jimenez, Jose Guijarro-Nuez, Javier Alegre-Abarrategui
    International Journal of Molecular Sciences.2023; 24(17): 13199.     CrossRef
  • Case Study 6: The Diagnostic Challenge of a 75-Year-Old Man Who Had, Then Didn’t Have, Then Did Have Alzheimer’s Disease
    Sergio A. Ramírez-Salazar, Cassie MacRae, Mel B. Feany, Michael Miller, Hyun-Sik Yang, Mary-Ellen Meadows, Scott M. McGinnis, David Silbersweig, Seth A. Gale, Kirk R. Daffner
    The Journal of Neuropsychiatry and Clinical Neurosciences.2023; 35(4): 325.     CrossRef
  • Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
    Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
    Brain Sciences.2023; 13(10): 1471.     CrossRef
  • A Unique Perspective on Lead Compounds for Dementia with the Lewy Body
    Menaka Subramani, Amuthalakshmi Sivaperuman, Ramalakshmi Natarajan, Keerthana Dhinakaran
    Medicinal Chemistry.2023; 19(10): 946.     CrossRef
  • Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac 123I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT
    Shintaro Saito, Kenichi Nakajima, Takayuki Shibutani, Hiroshi Wakabayashi, Hiroto Yoneyama, Takahiro Konishi, Hiroshi Mori, Aki Takata, Seigo Kinuya
    Annals of Nuclear Cardiology.2023; 9(1): 61.     CrossRef
  • Comparison of Taiwanese and European Calibration Factors for Heart-to-Mediastinum Ratio in Multicenter 123I-mIBG Phantom Studies
    Koichi Okuda, Kenichi Nakajima, Guang-Uei Hung, Hao-Ting Wu, Derk O. Verschure, Hein J. Verberne, Chiemi Kitamura
    Annals of Nuclear Cardiology.2023; 9(1): 54.     CrossRef
  • Clinical biomarkers for Lewy body diseases
    Mai M. Abdelmoaty, Eugene Lu, Rana Kadry, Emma G. Foster, Shaurav Bhattarai, R. Lee Mosley, Howard E. Gendelman
    Cell & Bioscience.2023;[Epub]     CrossRef
  • Proteomic comparison between non‐purified cerebrospinal fluid and cerebrospinal fluid‐derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia
    Yael Hirschberg, Natalia Valle‐Tamayo, Oriol Dols‐Icardo, Sebastiaan Engelborghs, Bart Buelens, Roosmarijn E. Vandenbroucke, Yannick Vermeiren, Kurt Boonen, Inge Mertens
    Journal of Extracellular Vesicles.2023;[Epub]     CrossRef
  • The connection between cerebral amyloid angiopathy and Alzheimer’s disease
    Hans Rolf Jäger
    European Radiology.2023; 34(4): 2171.     CrossRef
  • Autonomic symptoms are predictive of dementia with Lewy bodies
    Wenzheng Hu, Shuai Liu, Fei Wang, Han Zhu, Xiaoshan Du, Lingyun Ma, Jinghuan Gan, Hao Wu, Xiaodan Wang, Yong Ji
    Parkinsonism & Related Disorders.2022; 95: 1.     CrossRef
  • Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?
    Daniele Urso, Valentina Gnoni, Marco Filardi, Giancarlo Logroscino
    Frontiers in Psychiatry.2022;[Epub]     CrossRef
  • Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies
    Yian Gu, Anton Kociolek, Kayri K. Fernandez, Stephanie A. Cosentino, Carolyn Wei Zhu, Zhezhen Jin, James B. Leverenz, Yaakov B. Stern
    Neurology.2022;[Epub]     CrossRef
  • Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson’s Disease Using Quantitative Indices of 18F-FP-CIT PET/CT
    Miju Cheon, Seung Min Kim, Sang-Won Ha, Min Ju Kang, Hea-Eun Yang, Jang Yoo
    Diagnostics.2022; 12(6): 1402.     CrossRef
  • The promise of amplification assays for accurate early detection of α-synucleinopathies: A review
    Regina Kurapova, Leonidas Chouliaras, John T. O'Brien
    Experimental Gerontology.2022; 165: 111842.     CrossRef
  • Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder
    Annette Janzen, David Vadasz, Jan Booij, Markus Luster, Damiano Librizzi, Martin T. Henrich, Lars Timmermann, Mahboubeh Habibi, Elisabeth Sittig, Geert Mayer, Fanni Geibl, Wolfgang Oertel
    Journal of Parkinson's Disease.2022; 12(6): 1921.     CrossRef
  • A Systematic Review and Comparison of Neurocognitive Features of Late-Life Attention-Deficit/Hyperactivity Disorder and Dementia With Lewy Bodies
    Jennifer L. Prentice, Morgan J. Schaeffer, Alexandra K. Wall, Brandy L. Callahan
    Journal of Geriatric Psychiatry and Neurology.2021; 34(5): 466.     CrossRef
  • Dementia with Lewy bodies in first-generation immigrants in a European memory clinic
    Kurt Segers, Florence Benoit, Jean-Marie Meyts, Gérald Glibert, Sophie Levy, Murielle Surquin
    Acta Neurologica Belgica.2021; 121(1): 219.     CrossRef
  • The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer’s disease by cerebral perfusion SPECT-comparison to CIScore
    Gaku Honda, Shigeki Nagamachi, Masanari Nonokuma, Koichi Takano, Yasuo Kuwabara, Kengo Yoshimitsu, Hitoshi Iida, Koji Ogomori, Hiroaki Kawasaki, Yoshio Tsuboi
    Japanese Journal of Radiology.2021; 39(2): 198.     CrossRef
  • Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease
    Xue-Bing Ding, Xin-Xin Wang, Dan-Hao Xia, Han Liu, Hai-Yan Tian, Yu Fu, Yong-Kang Chen, Chi Qin, Jiu-Qi Wang, Zhi Xiang, Zhong-Xian Zhang, Qin-Chen Cao, Wei Wang, Jia-Yi Li, Erxi Wu, Bei-Sha Tang, Ming-Ming Ma, Jun-Fang Teng, Xue-Jing Wang
    Nature Medicine.2021; 27(3): 411.     CrossRef
  • Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences
    Dariusz Koziorowski, Monika Figura, Łukasz M. Milanowski, Stanisław Szlufik, Piotr Alster, Natalia Madetko, Andrzej Friedman
    Cells.2021; 10(3): 656.     CrossRef
  • Advances in computerized MRI‐based biomarkers in Alzheimer’s disease
    Raymond Wong, Yishan Luo, Vincent Chung-tong Mok, Lin Shi
    Brain Science Advances.2021; 7(1): 26.     CrossRef
  • Convolutional neural network-based automatic heart segmentation and quantitation in 123I-metaiodobenzylguanidine SPECT imaging
    Shintaro Saito, Kenichi Nakajima, Lars Edenbrandt, Olof Enqvist, Johannes Ulén, Seigo Kinuya
    EJNMMI Research.2021;[Epub]     CrossRef
  • A direct comparison of the 2005 and 2017 criteria for dementia with Lewy bodies
    Kurt Segers, Florence Benoit, Jean‐Marie Meyts, Gerald Glibert, Murielle Surquin
    Psychogeriatrics.2020; 20(5): 785.     CrossRef
  • Calibrated scintigraphic imaging procedures improve quantitative assessment of the cardiac sympathetic nerve activity
    Koichi Okuda, Kenichi Nakajima, Chiemi Kitamura, Yumiko Kirihara, Mitsumasa Hashimoto, Seigo Kinuya
    Scientific Reports.2020;[Epub]     CrossRef
Case Report
‘Hummingbird’ Sign in a Patient with Guam Parkinsonism-Dementia Complex
Tianrong Yeo, Louis CS Tan
J Mov Disord. 2017;10(3):145-148.   Published online August 8, 2017
DOI: https://doi.org/10.14802/jmd.17025
  • 6,792 View
  • 137 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary Material
We present a case of a 71-year-old male Chamorro patient from Guam who presented with progressive supranuclear palsy (PSP)-Richardson’s syndrome. Considering his strong family history of parkinsonism and a PSP phenotype, he was clinically diagnosed with Guam parkinsonism-dementia complex (PDC). Magnetic resonance imaging (MRI) of the brain revealed prominent midbrain atrophy with preserved pontine volume, forming the ‘hummingbird’ sign, which has not been described before in Guam PDC. Molecular analysis of the chromosome 9 open reading frame 72 gene (C9orf72) showed only 6 GGGGCC repeats. We discuss the clinico-pathological similarities and differences between PSP and Guam PDC, and highlight the topography of neuropathological changes seen in Guam PDC to explain the appearance of the ‘hummingbird’ sign on MRI.

Citations

Citations to this article as recorded by  
  • Discriminative pattern of reduced cerebral blood flow in Parkinson’s disease and Parkinsonism-Plus syndrome: an ASL-MRI study
    Lina Cheng, Xiaoyan Wu, Ruomi Guo, Yuzhou Wang, Wensheng Wang, Peng He, Hanbo Lin, Jun Shen
    BMC Medical Imaging.2020;[Epub]     CrossRef
  • Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics
    Jacky Ganguly, Mandar Jog
    Frontiers in Neurology.2020;[Epub]     CrossRef
Original Article
The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinson’s Disease
Ji In Kim, Mun Kyung Sunwoo, Young H. Sohn, Phil Hyu Lee, Jin Y. Hong
J Mov Disord. 2016;9(3):152-159.   Published online September 21, 2016
DOI: https://doi.org/10.14802/jmd.16020
  • 20,741 View
  • 406 Download
  • 37 Web of Science
  • 37 Crossref
AbstractAbstract PDF
Objective
To explore whether the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) can be used to screen for dementia or mild cognitive impairment (MCI) in less educated patients with Parkinson’s disease (PD).
Methods
We reviewed the medical records of PD patients who had taken the Korean MMSE (K-MMSE), Korean MoCA (K-MoCA), and comprehensive neuropsychological tests. Predictive values of the K-MMSE and K-MoCA for dementia or MCI were analyzed in groups divided by educational level.
Results
The discriminative powers of the K-MMSE and K-MoCA were excellent [area under the curve (AUC) 0.86–0.97] for detecting dementia but not for detecting MCI (AUC 0.64–0.85). The optimal screening cutoff values of both tests increased with educational level for dementia (K-MMSE < 15 for illiterate, < 20 for 0.5–3 years of education, < 23 for 4–6 years, < 25 for 7–9 years, and < 26 for 10 years or more; K-MoCA < 7 for illiterate, < 13 for 0.5–3 years, < 16 for 4–6 years, < 19 for 7–9 years, < 20 for 10 years or more) and MCI (K-MMSE < 19 for illiterate, < 26 for 0.5–3 years, < 27 for 4–6 years, < 28 for 7–9 years, and < 29 for 10 years or more; K-MoCA < 13 for illiterate, < 21 for 0.5–3 years, < 23 for 4–6 years, < 25 for 7–9 years, < 26 for 10 years or more).
Conclusion
Both MMSE and MoCA can be used to screen for dementia in patients with PD, regardless of educational level; however, neither test is sufficient to discriminate MCI from normal cognition without additional information.

Citations

Citations to this article as recorded by  
  • Neurocognitive correlates of semantic memory navigation in Parkinson’s disease
    Felipe Diego Toro-Hernández, Joaquín Migeot, Nicolás Marchant, Daniela Olivares, Franco Ferrante, Raúl González-Gómez, Cecilia González Campo, Sol Fittipaldi, Gonzalo M. Rojas-Costa, Sebastian Moguilner, Andrea Slachevsky, Pedro Chaná Cuevas, Agustín Ibáñ
    npj Parkinson's Disease.2024;[Epub]     CrossRef
  • Influence of cognitive reserve on cognitive and motor function in α-synucleinopathies: A systematic review and multilevel meta-analysis
    Isaac Saywell, Lauren Foreman, Brittany Child, Alexander L. Phillips-Hughes, Lyndsey Collins-Praino, Irina Baetu
    Neuroscience & Biobehavioral Reviews.2024; 161: 105672.     CrossRef
  • Comparing Montreal Cognitive Assessment Performance in Parkinson’s Disease Patients: Age- and Education-Adjusted Cutoffs vs. Machine Learning
    Kyeongmin Baek, Young Min Kim, Han Kyu Na, Junki Lee, Dong Ho Shin, Seok-Jae Heo, Seok Jong Chung, Kiyong Kim, Phil Hyu Lee, Young H. Sohn, Jeehee Yoon, Yun Joong Kim
    Journal of Movement Disorders.2024; 17(2): 171.     CrossRef
  • Association between executive and physical functions in people with Parkinson’s disease
    Fatma Kübra Çekok, Turhan Kahraman, Arzu Genç, Gözde Duran, Berril Dönmez Çolakoğlu, Deniz Yerlikaya, Görsev Yener
    Somatosensory & Motor Research.2023; : 1.     CrossRef
  • Effect of Education on Discriminability of Montreal Cognitive Assessment Compared to Mini-Mental State Examination
    Haeyoon Kim, Seonyeong Yang, Jaesel Park, Byeong Chae Kim, Kyung-Ho Yu, Yeonwook Kang
    Dementia and Neurocognitive Disorders.2023; 22(2): 69.     CrossRef
  • Altered connectivity in the cognitive control-related prefrontal cortex in Parkinson’s disease with rapid eye movement sleep behavior disorder
    Jinjing Liu, Xiaoya Zou, Jinming Gu, Qian Yu, Zhaoying Dong, Hongzhou Zuo, Xiaocui Chen, Xinyi Du, Dezhi Zou, Yu Han, Juan Peng, Oumei Cheng
    Brain Imaging and Behavior.2023; 17(6): 702.     CrossRef
  • Resting-state electroencephalographic characteristics related to mild cognitive impairments
    Seong-Eun Kim, Chanwoo Shin, Junyeop Yim, Kyoungwon Seo, Hokyoung Ryu, Hojin Choi, Jinseok Park, Byoung-Kyong Min
    Frontiers in Psychiatry.2023;[Epub]     CrossRef
  • Floor and ceiling effects on the Montreal Cognitive Assessment in patients with Parkinson’s disease in Brazil
    Brenda Hanae Bentes Koshimoto, Pedro Renato de Paula Brandão, Vanderci Borges, Henrique Ballalai Ferraz, Artur Francisco Schumacher-Schuh, Carlos Roberto de Mello Rieder, Maira Rozenfeld Olchik, Ignacio Fernandez Mata, Vitor Tumas, Bruno Lopes Santos-Loba
    Dementia & Neuropsychologia.2023;[Epub]     CrossRef
  • Alerting network alteration in isolated rapid eye movement sleep behavior disorder patients with mild cognitive impairment
    El Jeong, Kwang Su Cha, Hye-Rim Shin, Eun Young Kim, Jin-Sun Jun, Tae-Joon Kim, Jung-Ick Byun, Jung-Won Shin, Jun-Sang Sunwoo, Ki-Young Jung
    Sleep Medicine.2022; 89: 10.     CrossRef
  • What Do These Findings Tell Us? Comment on Tinella et al. Cognitive Efficiency and Fitness-to-Drive along the Lifespan: The Mediation Effect of Visuospatial Transformations. Brain Sci. 2021, 11, 1028
    Robert E. Kelly, Anthony O. Ahmed, Matthew J. Hoptman
    Brain Sciences.2022; 12(2): 165.     CrossRef
  • Association Between Lipid Accumulation Product and Cognitive Function in Hypertensive Patients With Normal Weight: Insight From the China H-type Hypertension Registry Study
    Yanyou Xie, Junpei Li, Guotao Yu, Xinlei Zhou, Wei Zhou, Lingjuan Zhu, Tao Wang, Xiao Huang, Huihui Bao, Xiaoshu Cheng
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Accuracy of Machine Learning Using the Montreal Cognitive Assessment for the Diagnosis of Cognitive Impairment in Parkinson’s Disease
    Junbeom Jeon, Kiyong Kim, Kyeongmin Baek, Seok Jong Chung, Jeehee Yoon, Yun Joong Kim
    Journal of Movement Disorders.2022; 15(2): 132.     CrossRef
  • Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism
    Laurent Cleret de Langavant, Emmanuel Roze, Aimée Petit, Benoit Tressières, Amin Gharbi‐Meliani, Hugo Chaumont, Patrick Pierre Michel, Anne‐Catherine Bachoud‐Lévi, Philippe Remy, Régine Edragas, Annie Lannuzel
    Movement Disorders.2022; 37(12): 2355.     CrossRef
  • Obesity marker trajectories and cognitive impairment in older adults: a 10-year follow-up in Taichung community health study for elders
    Tsai-Chung Li, Chia-Ing Li, Chiu-Shong Liu, Chih-Hsueh Lin, Shing-Yu Yang, Cheng-Chieh Lin
    BMC Psychiatry.2022;[Epub]     CrossRef
  • The Six‐item Clock‐Drawing Scoring System: a rapid screening for cognitive impairment in Parkinson's disease
    Praween Lolekha, Chanya Tangkanakul, Thanida Saengchatri, Pornlapat Kulkeartprasert
    Psychogeriatrics.2021; 21(1): 24.     CrossRef
  • Lack of association between proton pump inhibitor use and brain aging: a cross-sectional study
    Nayeon Ahn, Stefan Frenzel, Katharina Wittfeld, Robin Bülow, Henry Völzke, Markus M. Lerch, Jean-Francois Chenot, Ulf Schminke, Michael Nolde, Ute Amann, Christa Meisinger, Jakob Linseisen, Sebastian E. Baumeister, Hans Jörgen Grabe, Ina-Maria Rückert-Ehe
    European Journal of Clinical Pharmacology.2021; 77(7): 1039.     CrossRef
  • A Comprehensive Meta-analysis on Short-term and Working Memory Dysfunction in Parkinson’s Disease
    Ari Alex Ramos, Liana Machado
    Neuropsychology Review.2021; 31(2): 288.     CrossRef
  • The role of APOE in cognitive trajectories and motor decline in Parkinson’s disease
    Sungyang Jo, Seon-Ok Kim, Kye Won Park, Seung Hyun Lee, Yun Su Hwang, Sun Ju Chung
    Scientific Reports.2021;[Epub]     CrossRef
  • Altered regional homogeneity and connectivity in cerebellum and visual-motor relevant cortex in Parkinson's disease with rapid eye movement sleep behavior disorder
    Jinjing Liu, Guangying Shuai, Weidong Fang, Yingcheng Zhu, Huiyue Chen, Yuchan Wang, Qun Li, Yu Han, Dezhi Zou, Oumei Cheng
    Sleep Medicine.2021; 82: 125.     CrossRef
  • Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease
    Minkyeong Kim, Seulki Yoo, Doyeon Kim, Jin Whan Cho, Ji Sun Kim, Jong Hyun Ahn, Jun Kyu Mun, Inyoung Choi, Seung-Kyun Lee, Jinyoung Youn
    Neurological Sciences.2021; 42(12): 5297.     CrossRef
  • Regional Neural Activity Changes in Parkinson’s Disease-Associated Mild Cognitive Impairment and Cognitively Normal Patients
    Yilan Xing, Shishun Fu, Meng Li, Xiaofen Ma, Mengchen Liu, Xintong Liu, Yan Huang, Guang Xu, Yonggang Jiao, Hong Wu, Guihua Jiang, Junzhang Tian
    Neuropsychiatric Disease and Treatment.2021; Volume 17: 2697.     CrossRef
  • Understanding fatigue in progressive supranuclear palsy
    Jong Hyeon Ahn, Joomee Song, Dong Yeong Lee, Jinyoung Youn, Jin Whan Cho
    Scientific Reports.2021;[Epub]     CrossRef
  • Motor and Non-motor Symptoms Associated With Exercise Behavior in Parkinson's Disease Patients: Factors Differ Between Patients With and Without Postural Instability
    Joomee Song, Jinyoung Youn, Young Eun Huh, Jun Kyu Mun, Jong Hyeon Ahn, Dongyeong Lee, Woo Young Shin, Jin Whan Cho
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Brainstem-Predominant Lewy-Related Pathology in a Patient with Parkinson’s Disease without Dementia
    Ji-Hyun Choi, Sung-Hye Park, Sung Sup Park, Beomseok Jeon
    Journal of Movement Disorders.2020; 13(1): 74.     CrossRef
  • Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease
    Etienne Goubault, Sarah Bogard, Pierre J. Blanchet, Erwan Bézard, Claude Vincent, Davide Martino, Justyna Sarna, Oury Monchi, Christian Duval
    Tremor and Other Hyperkinetic Movements.2020;[Epub]     CrossRef
  • Cortical thinning pattern according to differential nigrosome involvement in patients with Parkinson’s disease
    Na-Young Shin, Bo-Hyun Kim, Eunkyeong Yun, Uicheul Yoon, Jong-Min Lee, Young Hee Sung, Eung Yeop Kim
    NeuroImage: Clinical.2020; 28: 102382.     CrossRef
  • Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
    Kye Won Park, Sungyang Jo, Seung Hyun Lee, Yun Su Hwang, Dagyo Lee, Ho-Sung Ryu, Sun Ju Chung
    Journal of Movement Disorders.2020; 13(3): 205.     CrossRef
  • The changes of exercise pattern and clinical symptoms in patients with Parkinson's disease in the era of COVID-19 pandemic
    Joomee Song, Jong Hyeon Ahn, Inyoung Choi, Jun Kyu Mun, Jin Whan Cho, Jinyoung Youn
    Parkinsonism & Related Disorders.2020; 80: 148.     CrossRef
  • Pesticide exposure and cognitive decline in a rural South Korean population
    Jae-Yeop Kim, Sung-jin Park, Sung-Kyung Kim, Chang-Soo Kim, Tae-Hei Kim, Seong-Ho Min, Sung-Soo Oh, Sang-Baek Koh, Stephen D. Ginsberg
    PLOS ONE.2019; 14(3): e0213738.     CrossRef
  • Cut-off points of the Portuguese version of the Montreal Cognitive Assessment for cognitive evaluation in Parkinson’s disease
    Kelson James Almeida, Larissa Clementino Leite de Sá Carvalho, Tomásia Henrique Oliveira de Holanda Monteiro, Paulo Cesar de Jesus Gonçalves Júnior, Raimundo Nonato Campos-Sousa
    Dementia & Neuropsychologia.2019; 13(2): 210.     CrossRef
  • Effects of Acupuncture Therapy on MCI Patients Using Functional Near-Infrared Spectroscopy
    Usman Ghafoor, Jun-Hwan Lee, Keum-Shik Hong, Sang-Soo Park, Jieun Kim, Ho-Ryong Yoo
    Frontiers in Aging Neuroscience.2019;[Epub]     CrossRef
  • Validation of the Conversion between the Mini-Mental State Examination and Montreal Cognitive assessment in Korean Patients with Parkinson’s Disease
    Ryul Kim, Han-Joon Kim, Aryun Kim, Mi-Hee Jang, Hyun Jeong Kim, Beomseok Jeon
    Journal of Movement Disorders.2018; 11(1): 30.     CrossRef
  • Further evidence for a distinctive atypical degenerative parkinsonism in the Caribbean: A new cluster in the French West Indian Island of Martinique
    Annie Lannuzel, Régine Edragas, Angéla Lackmy, Benoit Tressières, Véronique Pelonde, Mireille Edimo Nana Kaptué, Sylvie Mécharles, Alexis Demas, Billy François, Eavan McGovern, Marie Vidailhet, Bertrand Gaymard, Emmanuel Roze
    Journal of the Neurological Sciences.2018; 388: 214.     CrossRef
  • Follow-up of the manganese-exposed workers healthy cohort (MEWHC) and biobank management from 2011 to 2017 in China
    Yanting Zhou, Xiaoting Ge, Yuefei Shen, Lian Qin, Yaoqiu Zhong, Chao Jiang, Cheng Su, Jinyu Huang, Suzhen Lin, Defu Li, Hong Cheng, Fu Wei, Songfeng Ou, Yunfeng Zou, Xiaobo Yang
    BMC Public Health.2018;[Epub]     CrossRef
  • The Prevalence of Cerebral Microbleeds in Non-Demented Parkinson's Disease Patients
    Kyeong Joon Kim, Yun Jung Bae, Jong-Min Kim, Beom Joon Kim, Eung Seok Oh, Ji Young Yun, Ji Seon Kim, Han-Joon Kim
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Validation of MoCA-MMSE Conversion Scales in Korean Patients with Cognitive Impairments
    Young Ik Jung, Eun Hye Jeong, Heejin Lee, Junghee Seo, Hyun-Jeong Yu, Jin Y. Hong, Mun Kyung Sunwoo
    Dementia and Neurocognitive Disorders.2018; 17(4): 148.     CrossRef
  • Validation of the Korean Version of the Scale for Outcomes in Parkinson’s Disease-Autonomic
    Ji-Young Kim, In-Uk Song, Seong-Beom Koh, Tae-Beom Ahn, Sang Jin Kim, Sang-Myung Cheon, Jin Whan Cho, Yun Joong Kim, Hyeo-Il Ma, Mee-Young Park, Jong Sam Baik, Phil Hyu Lee, Sun Ju Chung, Jong-Min Kim, Han-Joon Kim, Young-Hee Sung, Do Young Kwon, Jae-Hyeo
    Journal of Movement Disorders.2017; 10(1): 29.     CrossRef
Case Report
Creutzfeldt-Jakob Disease in a Tertiary Care Hospital in Thailand: A Case Series and Review of the Literature
Praween Lolekha, Ahmed Rasheed, Chutanat Yotsarawat
J Mov Disord. 2015;8(3):136-140.   Published online September 10, 2015
DOI: https://doi.org/10.14802/jmd.15014
  • 18,480 View
  • 82 Download
  • 8 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Creutzfeldt-Jakob Disease (CJD) is an incurable and inevitably fatal neurodegenerative disorder. Although CJD has a worldwide distribution, there are no official statistics on CJD in Thailand. A diagnosis of CJD is suspected when a patient develops rapidly progressive dementia with myoclonus. However, CJD may be mistaken for a variety of illnesses because its initial presentation frequently consists of non-specific symptoms. Here, we examined cases of sporadic CJD (sCJD) from Thammasat University Hospital (a tertiary care hospital in Thailand) between January 1, 2012 and December 31, 2014. Three cases of probable and possible sCJD were collected. All cases presented with rapidly progressive cognitive dysfunction accompanied by spontaneous myoclonus. Classical electroencehalography changes and typical abnormal MRI features were observed. All of the cases died within a period of 8 months. None of the patients underwent brain biopsy. Our findings raise questions about the prevalence of CJD in Thailand, which needs further study.

Citations

Citations to this article as recorded by  
  • Sporadic Creutzfeldt-Jakob disease: Brain MRI lesion features from 2 cases reports
    Hoang Dinh Au, Nguyen Thu Lan, Nguyen Thai Binh, Le Tuan Linh, Ma Mai Hien, Nguyen Minh Duc
    Radiology Case Reports.2024; 19(3): 939.     CrossRef
  • A systemic analysis of Creutzfeldt Jakob disease cases in Asia
    Urwah Rasheed, Sana Khan, Minahil Khalid, Aneeqa Noor, Saima Zafar
    Prion.2024; 18(1): 11.     CrossRef
  • The importance of ongoing international surveillance for Creutzfeldt–Jakob disease
    Neil Watson, Jean-Philippe Brandel, Alison Green, Peter Hermann, Anna Ladogana, Terri Lindsay, Janet Mackenzie, Maurizio Pocchiari, Colin Smith, Inga Zerr, Suvankar Pal
    Nature Reviews Neurology.2021; 17(6): 362.     CrossRef
  • Case series of Creutzfeldt-Jakob disease in a third-level hospital in Quito
    Germaine Eleanor Torres Herrán, Andrés Damián Ortega Herrera, Braulio Martinez Burbano, Marcos Serrano-Dueñas, María Angélica Ortiz Yepez, Raúl Alberto Barrera Madera, Luis Alfredo Masabanda Campaña, Guillermo David Baño Jiménez, Denny Maritza Santos Salt
    BMC Neurology.2018;[Epub]     CrossRef
  • An Evaluation of Rapidly Progressive Dementia Culminating in a Diagnosis of Creutzfeldt–Jakob Disease
    Parmvir Parmar, Curtis L. Cooper, Daniel Kobewka
    Case Reports in Infectious Diseases.2018; 2018: 1.     CrossRef
  • Diffusion-weighted MRI abnormalities antedate the onset of sporadic Creutzfeldt-Jakob disease
    Keisuke Suzuki, Akiko Kawasaki, Takahide Nagashima, Koichi Hirata
    Neurology.2016; 87(8): 843.     CrossRef
Original Article
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
Yoon-Sang Oh, Joong-Seok Kim, Phil Hyu Lee
J Mov Disord. 2015;8(2):98-102.   Published online May 31, 2015
DOI: https://doi.org/10.14802/jmd.15041
  • 20,651 View
  • 256 Download
  • 28 Web of Science
  • 29 Crossref
AbstractAbstract PDF
Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine is efficacious for the treatment of dementia in Parkinson’s disease (PD). We investigated the efficacy of rivastigmine for BPSD in patients with Parkinson’s disease dementia (PDD).
Methods Twenty-three patients in whom cognitive impairment occurred at least one year after a diagnosis of PD participated in this open-label trial. Cognitive, psychiatric, and motor symptoms were assessed before and after 24 weeks of treatment with rivastigmine using unstructured clinical assessments and rating scales including the Unified Parkinson’s Disease Rating Scale, Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory.
Results Age (± standard deviation) was 74.7 ± 5.9 years, average duration of PD was 3.5 ± 3.7 years, Hoehn and Yahr scores were 2.2 ± 0.8, and baseline MMSE scores were 19.1 ± 4.2. Improvements in global mental symptoms and neuropsychiatric symptoms were significant; among them, hallucination, depression and appetite changes improved. Caregiver distress significantly decreased, including distress resulting from hallucinations, depression, apathy, and appetite changes.
Conclusions Although controlled trials are required, the findings suggest that rivastigmine is useful for control of several neuropsychiatric symptoms and beneficial for caregiver distress in patients with PDD.

Citations

Citations to this article as recorded by  
  • The treatment of behavioural and psychological symptoms in dementia: pragmatic recommendations
    Camille Mercier, Victoria Rollason, Mohamed Eshmawey, Aline Mendes, Giovanni B. Frisoni
    Psychogeriatrics.2024;[Epub]     CrossRef
  • Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review
    Efthalia Angelopoulou, Evangelia Stanitsa, Claire Chrysanthi Karpodini, Anastasia Bougea, Dionysia Kontaxopoulou, Stella Fragkiadaki, Christos Koros, Vasiliki Epameinondas Georgakopoulou, George Fotakopoulos, Yiannis Koutedakis, Christina Piperi, Sokratis
    Medicina.2023; 59(8): 1454.     CrossRef
  • Parkinsonism and dementia
    Christos Koros, Leonidas Stefanis, Nikolaos Scarmeas
    Journal of the Neurological Sciences.2022; 433: 120015.     CrossRef
  • Current concepts in treating mild cognitive impairment in Parkinson's disease
    Jay S. Schneider, Sandhya Kortagere
    Neuropharmacology.2022; 203: 108880.     CrossRef
  • Apathy in Parkinson’s Disease: Defining the Park Apathy Subtype
    Ségolène De Waele, Patrick Cras, David Crosiers
    Brain Sciences.2022; 12(7): 923.     CrossRef
  • Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
    Łucja Justyna Walczak-Nowicka, Mariola Herbet
    International Journal of Molecular Sciences.2021; 22(17): 9290.     CrossRef
  • Diagnosis and treatment of old-onset Parkinson's disease
    久大 立花
    Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics.2021; 58(3): 341.     CrossRef
  • Neuropsychiatrische Störungen bei idiopathischem Parkinson-Syndrom
    Mario Paulig
    Nervenheilkunde.2021; 40(10): 752.     CrossRef
  • Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson’s Disease
    Katie Pizzolato, David Thacker, Nicole Del Toro-Pagán, Abeer Hanna, Jacques Turgeon, Adriana Matos, Nishita Amin, Veronique Michaud
    Medicina.2021; 57(10): 1107.     CrossRef
  • Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy
    Paolo Morana, Federico Mucci, Stefano Baroni, Alessandra Della Vecchia, Armando Piccinni, Benedetto Morana, Donatella Marazziti
    Clinical Case Reports.2020; 8(2): 254.     CrossRef
  • Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
    Kathy Dujardin, Véronique Sgambato
    Frontiers in Neuroscience.2020;[Epub]     CrossRef
  • Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson’s Disease, and Multiple Sclerosis: Diagnosis and Treatment
    Susan K. Conroy, Katherine B. Brownlowe, Thomas W. McAllister
    FOCUS.2020; 18(2): 150.     CrossRef
  • Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
    Claudia Lazcano-Ocampo, Yi Min Wan, Daniel J van Wamelen, Lucia Batzu, Iro Boura, Nataliya Titova, Valentina Leta, Mubasher Qamar, Pablo Martinez-Martin, K Ray Chaudhuri
    Expert Review of Neurotherapeutics.2020; 20(5): 477.     CrossRef
  • Diagnosis, treatment and management of apathy in Parkinson’s disease: a scoping review
    Bria Mele, Shinia Van, Jayna Holroyd-Leduc, Zahinoor Ismail, Tamara Pringsheim, Zahra Goodarzi
    BMJ Open.2020; 10(9): e037632.     CrossRef
  • Pharmacological treatment of apathy in Lewy body disorders: A systematic review
    Jennifer Liu, Christine A. Cooper, Daniel Weintraub, Nabila Dahodwala
    Parkinsonism & Related Disorders.2019; 60: 14.     CrossRef
  • Current treatment of behavioral and cognitive symptoms of Parkinson's disease
    Irena Rektorova
    Parkinsonism & Related Disorders.2019; 59: 65.     CrossRef
  • Approach to the management of psychosis in Parkinson’s disease
    Abhishek Lenka, Vasanthi Gomathinayagam, Laxman Bahroo
    Annals of Movement Disorders.2019; 2(3): 83.     CrossRef
  • Risk factors for non-motor symptoms in Parkinson's disease
    Johan Marinus, Kangdi Zhu, Connie Marras, Dag Aarsland, Jacobus J van Hilten
    The Lancet Neurology.2018; 17(6): 559.     CrossRef
  • The efficacy of pharmacological approaches to therapy of the apathy syndrome in dementia disorders (the review)
    A. S. Avedisova, A. B. Guekht, K. V. Zakharova, R. G. Akzhigitov
    Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2018; 118(4): 126.     CrossRef
  • Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle
    Rita Moretti, Paola Caruso, Matteo Dal Ben
    Parkinson's Disease.2017; 2017: 1.     CrossRef
  • Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature
    Philip E. Mosley, Rebecca Moodie, Nadeeka Dissanayaka
    Journal of Geriatric Psychiatry and Neurology.2017; 30(5): 235.     CrossRef
  • Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment
    Stephane Thobois, Stephane Prange, Véronique Sgambato-Faure, Léon Tremblay, Emmanuel Broussolle
    Current Neurology and Neuroscience Reports.2017;[Epub]     CrossRef
  • Parkinson's disease psychosis: presentation, diagnosis and management
    Ruth B Schneider, Julia Iourinets, Irene H Richard
    Neurodegenerative Disease Management.2017; 7(6): 365.     CrossRef
  • Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson’s Disease
    Yunlong Zhang, Feng Tan, Pingyi Xu, Shaogang Qu
    Neural Plasticity.2016; 2016: 1.     CrossRef
  • Neuropsychiatric Issues in Parkinson’s Disease
    Jeffrey W. Cooney, Mark Stacy
    Current Neurology and Neuroscience Reports.2016;[Epub]     CrossRef
  • Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists
    Daniel Martinez-Ramirez, Michael S Okun, Michael S Jaffee
    Neurodegenerative Disease Management.2016; 6(4): 319.     CrossRef
  • Pimavanserin for the treatment of Parkinson’s disease psychosis
    Ines Chendo, Joaquim J Ferreira
    Expert Opinion on Pharmacotherapy.2016; 17(15): 2115.     CrossRef
  • Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments
    Fleur Harrison, Liesbeth Aerts, Henry Brodaty
    Current Psychiatry Reports.2016;[Epub]     CrossRef
  • Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration
    Santiago Perez-Lloret, María Cecilia Peralta, Francisco J. Barrantes
    Expert Opinion on Pharmacotherapy.2016; 17(18): 2405.     CrossRef
Review Article
123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review
Eun Joo Chung, Sang Jin Kim
J Mov Disord. 2015;8(2):55-66.   Published online May 31, 2015
DOI: https://doi.org/10.14802/jmd.15015
  • 18,640 View
  • 197 Download
  • 45 Web of Science
  • 43 Crossref
AbstractAbstract PDF
Lewy body-related disorders are characterized by the presence of Lewy bodies and Lewy neurites, which have abnormal aggregations of α-synuclein in the nigral and extranigral areas, including in the heart. 123I-metaiodobenzylguanidine (MIBG) scintigraphy is a well-known tool to evaluate cardiac sympathetic denervation in the Lewy body-related disorders. MIBG scintigraphy showed low uptake of MIBG in the Lewy body-related disorders, including Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure and rapid eye movement sleep behavior disorder. This review summarizes previous results on the diagnostic applications of MIBG scintigraphy in Lewy body-related disorders.

Citations

Citations to this article as recorded by  
  • Sudden cardiac death in synucleinopathies
    Keivan Javanshiri, Tove Drakenberg, Mattias Haglund, Elisabet Englund
    Journal of Neuropathology & Experimental Neurology.2023; 82(3): 242.     CrossRef
  • Optimal Protocol and Clinical Usefulness of 123I-MIBG Cardiac Scintigraphy for Differentiation of Parkinson’s Disease and Dementia with Lewy Body from Non-Parkinson’s Diseases
    In Kook Chun
    Nuclear Medicine and Molecular Imaging.2023; 57(3): 145.     CrossRef
  • Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
    Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
    Brain Sciences.2023; 13(10): 1471.     CrossRef
  • Differentiating Dementia with Lewy Bodies from Alzheimer's Disease Using the Fall Risk Evaluation Questionnaire
    Masashi Tsujimoto, Keisuke Suzuki, Akinori Takeda, Naoki Saji, Takashi Sakurai, Yukihiko Washimi
    Internal Medicine.2022; 61(11): 1687.     CrossRef
  • Association of plasma α-synuclein with cardiac 123I-MIBG scintigraphy in early Parkinson’s disease
    Don Gueu Park, Juhee Kang, Young-Sil An, Jaerak Chang, Jung Han Yoon
    Neuroscience Letters.2022; 770: 136399.     CrossRef
  • Clinical and imaging evidence of brain-first and body-first Parkinson's disease
    Jacob Horsager, Karoline Knudsen, Michael Sommerauer
    Neurobiology of Disease.2022; 164: 105626.     CrossRef
  • Cardiac Alpha-Synuclein Is Present in Alpha-Synucleinopathies
    Keivan Javanshiri, Tove Drakenberg, Mattias Haglund, Elisabet Englund
    Journal of Parkinson's Disease.2022; 12(4): 1125.     CrossRef
  • Cardiac 123I-MIBG normal uptake values are population-specific: Results from a cohort of controls over 60 years of age
    G. Roberts, J.J. Lloyd, J.P.M. Kane, R. Durcan, S. Lawley, K. Howe, G.S. Petrides, J.T. O’Brien, A.J. Thomas
    Journal of Nuclear Cardiology.2021; 28(4): 1692.     CrossRef
  • Uniformity of cardiac 123I-MIBG uptake on SPECT images in older adults with normal cognition and patients with dementia
    Gemma Roberts, Jim J. Lloyd, Elizabeth Jefferson, Joseph P.M. Kane, Rory Durcan, Sarah Lawley, George S. Petrides, Kim Howe, Iftikhar Haq, John T. O’Brien, Alan J. Thomas
    Journal of Nuclear Cardiology.2021; 28(5): 2151.     CrossRef
  • Myocardial Sympathetic Innervation Imaging with MIBG in Dementia with Lewy Bodies
    Gagandeep Choudhary, Pradeep Bhambhvani
    Journal of Nuclear Cardiology.2021; 28(5): 2164.     CrossRef
  • Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease
    Juhee Kang, Jae Whan Kim, Hansol Heo, Jihyun Lee, Kwan Yong Park, Jung Han Yoon, Jaerak Chang
    Clinical and Translational Science.2021; 14(2): 606.     CrossRef
  • Gastrointestinal Dysfunction in Parkinson’s Disease
    Casper Skjærbæk, Karoline Knudsen, Jacob Horsager, Per Borghammer
    Journal of Clinical Medicine.2021; 10(3): 493.     CrossRef
  • Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson’s Disease—a Systematic Review
    Vasiliki Katsi, Ilias Papakonstantinou, Eirini Solomou, Alexios S. Antonopoulos, Charalambos Vlachopoulos, Konstantinos Tsioufis
    Current Hypertension Reports.2021;[Epub]     CrossRef
  • Lewy Body Dementias: A Coin with Two Sides?
    Ángela Milán-Tomás, Marta Fernández-Matarrubia, María Cruz Rodríguez-Oroz
    Behavioral Sciences.2021; 11(7): 94.     CrossRef
  • Cardiac Autonomic Dysfunction Is Associated with Severity of REM Sleep without Atonia in Isolated REM Sleep Behavior Disorder
    Sooyeoun You, Kyoung Sook Won, Keun Tae Kim, Hyang Woon Lee, Yong Won Cho
    Journal of Clinical Medicine.2021; 10(22): 5414.     CrossRef
  • A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index
    Fumi Sakamoto, Shinya Shiraishi, Koji Ogasawara, Noriko Tsuda, Masataka Nakagawa, Seiji Tomiguchi, Yasuyuki Yamashita
    Annals of Nuclear Medicine.2020; 34(6): 415.     CrossRef
  • Difference in cardiovascular response during orthostatic stress in Parkinson’s disease and multiple system atrophy
    Tomohiko Nakamura, Masashi Suzuki, Masamichi Ueda, Yumiko Harada, Masaaki Hirayama, Masahisa Katsuno
    Journal of Neural Transmission.2020; 127(10): 1377.     CrossRef
  • Striatal dopamine activity and myocardial 123I-metaiodobenzylguanidine uptake in early Parkinson's disease
    Yoon-Sang Oh, Joong-Seok Kim, Sang-Won Yoo, Eo-Jin Hwang, Chul Hyoung Lyoo, Kwang-Soo Lee
    Parkinsonism & Related Disorders.2019; 63: 156.     CrossRef
  • Initial Versus Follow-up Sequential Myocardial 123I-MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes
    Dong-Woo Ryu, Joong-Seok Kim, Jee-Eun Lee, Yoon-Sang Oh, Sang-Won Yoo, Ie Ryung Yoo, Kwang-Soo Lee
    Clinical Nuclear Medicine.2019; 44(4): 282.     CrossRef
  • Cardiac 123I-MIBG planar heart to mediastinum ratios depend on patient size; phantom studies suggest SPECT-CT could improve quantification
    Gemma Roberts, Jim J Lloyd, George S Petrides, John T O’Brien, Alan J Thomas
    Biomedical Physics & Engineering Express.2019; 6(1): 015011.     CrossRef
  • Does sympathetic dysfunction occur before denervation in pure autonomic failure?
    Ling Guo, Murray D. Esler, Carolina Sari, Sarah Phillips, Elisabeth A. Lambert, Nora E. Straznicky, Gavin W. Lambert, Susan J. Corcoran
    Clinical Science.2018; 132(1): 1.     CrossRef
  • Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in Parkinsonism: A preliminary study
    Dan Xu, Wenjia Zhu, Li Huo, Shikun Zhu, Fang Li, Han Wang
    Parkinsonism & Related Disorders.2018;[Epub]     CrossRef
  • Extensive Delayed Brain Atrophy after Resuscitation in a Patient with Multiple System Atrophy
    Sazuku Nisitani, Hirofumi Miyoshi, Yoji Katsuoka
    Frontiers in Neurology.2018;[Epub]     CrossRef
  • Optimizing Parkinson’s disease diagnosis: the role of a dual nuclear imaging algorithm
    J. William Langston, Jesse C. Wiley, Michele Tagliati
    npj Parkinson's Disease.2018;[Epub]     CrossRef
  • Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
    Ilaria Cova, Alberto Priori
    Journal of Neural Transmission.2018; 125(10): 1417.     CrossRef
  • Imaging the Autonomic Nervous System in Parkinson’s Disease
    Karoline Knudsen, Per Borghammer
    Current Neurology and Neuroscience Reports.2018;[Epub]     CrossRef
  • A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment
    Samuel D. Capouch, Martin R. Farlow, Jared R. Brosch
    Neurology and Therapy.2018; 7(2): 249.     CrossRef
  • The Utility of the Combined Use of 123I-FP-CIT and 123I-MIBG Myocardial Scintigraphy in Differentiating Parkinson’s Disease from Other Parkinsonian Syndromes
    Eiji Matsusue, Yoshio Fujihara, Kenichiro Tanaka, Yuki Aozasa, Manabu Shimoda, Hiroyuki Nakayasu, Kazuhiko Nakamura, Toshihide Ogawa
    Yonago Acta Medica.2018; 61(2): 117.     CrossRef
  • Correction of collimator-dependent differences in the heart-to-mediastinum ratio in 123I-metaiodobenzylguanidine cardiac sympathetic imaging: Determination of conversion equations using point-source imaging
    Yusuke Inoue, Yutaka Abe, Kei Kikuchi, Keiji Matsunaga, Ray Masuda, Kazutoshi Nishiyama
    Journal of Nuclear Cardiology.2017; 24(5): 1725.     CrossRef
  • Normal ‘heart’ in Parkinson's disease: is this a distinct clinical phenotype?
    J.‐S. Kim, H.‐E. Park, I.‐S. Park, Y.‐S. Oh, D.‐W. Ryu, I.‐U. Song, Y.‐A. Jung, I. R. Yoo, H.‐S. Choi, P. H. Lee, K.‐S. Lee
    European Journal of Neurology.2017; 24(2): 349.     CrossRef
  • Diagnosis of dementia with Lewy bodies: can 123I-IMP and 123I-MIBG scintigraphy yield new core features?
    Fumi Sakamoto, Shinya Shiraishi, Noriko Tsuda, Mamoru Hashimoto, Seiji Tomiguchi, Manabu Ikeda, Yasuyuki Yamashita
    The British Journal of Radiology.2017;[Epub]     CrossRef
  • Imaging Parkinson’s disease below the neck
    Per Borghammer, Karoline Knudsen, Tatyana D. Fedorova, David J. Brooks
    npj Parkinson's Disease.2017;[Epub]     CrossRef
  • The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes
    Naoto Uyama, Hideki Otsuka, Takayoshi Shinya, Yoichi Otomi, Masafumi Harada, Wataru Sako, Yuishin Izumi, Ryuji Kaji, Yuya Watanabe, Satoru Takashi, Yamato Kunikane
    Nuclear Medicine Communications.2017; 38(6): 487.     CrossRef
  • Cardiac sympathetic denervation and dementia in de novo Parkinson's disease: A 7-year follow-up study
    Mun Hee Choi, Jung Han Yoon, Suk Woo Yong
    Journal of the Neurological Sciences.2017; 381: 291.     CrossRef
  • Cardiovascular autonomic dysfunctions in elderly patients with essential tremor: comparison with healthy controls
    Joong-Seok Kim, Yoon-Sang Oh, Hyung-Eun Park, Si-Hoon Lee, Jeong-Wook Park, In-Uk Song, Jae-Young An, Hun-Jun Park, Byung-Chul Son, Kwang-Soo Lee
    Neurological Sciences.2016; 37(5): 711.     CrossRef
  • Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder
    Joong-Seok Kim, Hyung-Eun Park, Yoon-Sang Oh, Si-Hoon Lee, Jeong-Wook Park, Byung-chul Son, Kwang-Soo Lee
    Journal of the Neurological Sciences.2016; 362: 59.     CrossRef
  • [123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies
    J. J. van der Zande, J. Booij, P. Scheltens, P. G. H. M. Raijmakers, A. W. Lemstra
    European Journal of Nuclear Medicine and Molecular Imaging.2016; 43(6): 1060.     CrossRef
  • Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?
    Flavio Nobili, Dario Arnaldi, Silvia Morbelli
    European Journal of Nuclear Medicine and Molecular Imaging.2016; 43(6): 1056.     CrossRef
  • Imaging Systemic Dysfunction in Parkinson’s Disease
    Per Borghammer, Karoline Knudsen, David J. Brooks
    Current Neurology and Neuroscience Reports.2016;[Epub]     CrossRef
  • 123I‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)‐N‐(3‐fluoropropyl) nortropane single photon emission computed tomography and 123I‐metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study
    Pietro Tiraboschi, Angelo Corso, Ugo Paolo Guerra, Flavio Nobili, Arnoldo Piccardo, Maria Lucia Calcagni, Duccio Volterrani, Diego Cecchin, Mauro Tettamanti, Luigi Antelmi, Simone Vidale, Leonardo Sacco, Maria Merello, Stefano Stefanini, Anna Micheli, Pao
    Annals of Neurology.2016; 80(3): 368.     CrossRef
  • On the Utility of MIBG SPECT/CT in Evaluating Cardiac Sympathetic Dysfunction in Lewy Body Diseases
    Hayato Odagiri, Toru Baba, Yoshiyuki Nishio, Osamu Iizuka, Minoru Matsuda, Kentaro Inoue, Akio Kikuchi, Takafumi Hasegawa, Masashi Aoki, Atsushi Takeda, Yasuyuki Taki, Etsuro Mori, John Duda
    PLOS ONE.2016; 11(4): e0152746.     CrossRef
  • 123I-MIBG myocardial scintigraphy and neurocirculatory abnormalities in patients with dementia with Lewy bodies and Alzheimer's disease
    Joong-Seok Kim, Hyung-Eun Park, Yoon-Sang Oh, In-Uk Song, Dong-Won Yang, Jeong-Wook Park, Kwang-Soo Lee
    Journal of the Neurological Sciences.2015; 357(1-2): 173.     CrossRef
  • Orthostatic hypotension: managing a difficult problem
    Pearl K Jones, Brett H Shaw, Satish R Raj
    Expert Review of Cardiovascular Therapy.2015; 13(11): 1263.     CrossRef
Original Article
Neuropsychiatric Symptoms in Parkinson’s Disease Dementia Are Associated with Increased Caregiver Burden
Yoon-Sang Oh, Ji E. Lee, Phil Hyu Lee, Joong-Seok Kim
J Mov Disord. 2015;8(1):26-32.   Published online January 31, 2015
DOI: https://doi.org/10.14802/jmd.14019
  • 20,941 View
  • 119 Download
  • 37 Web of Science
  • 35 Crossref
AbstractAbstract PDF
Objective Neuropsychiatric symptoms are common in Parkinson’s disease dementia (PDD). Frequent and severe neuropsychiatric symptoms create high levels of distress for patients and caregivers, decreasing their quality of life. The aim of this study was to investigate neuropsychiatric symptoms that may contribute to increased caregiver burden in PDD patients.
Methods Forty-eight PDD patients were assessed using the 12-item Neuropsychiatric Inventory (NPI) to determine the frequency and severity of mental and behavioral problems. The Burden Interview and Caregiver Burden Inventory were used to evaluate caregiver burden.
Results All but one patient showed one or more neuropsychiatric symptoms. The three most frequent neuropsychiatric symptoms were apathy (70.8%) and anxiety (70.8%), followed by depression (68.7%). More severe neuropsychiatric symptoms were significantly correlated with increased caregiver burden. The domains of delusion, hallucination, agitation and aggression, anxiety, irritability and lability, and aberrant motor behavior were associated with caregiver stress. After controlling for age and other potential confounding variables, total NPI score was significantly associated with caregiver burden.
Conclusions The results of this study confirm that neuropsychiatric symptoms are frequent and severe in patients with PDD and are associated with increased caregiver distress. A detailed evaluation and management of neuropsychiatric symptoms in PDD patients appears necessary to improve patient quality of life and reduce caregiver burden.

Citations

Citations to this article as recorded by  
  • Caregiver Burden of Patients With Huntington’s Disease in South Korea
    Chan Young Lee, Chaewon Shin, Yun Su Hwang, Eungseok Oh, Manho Kim, Hyun Sook Kim, Sun Ju Chung, Young Hee Sung, Won Tae Yoon, Jin Whan Cho, Jae-Hyeok Lee, Han-Joon Kim, Hee Jin Chang, Beomseok Jeon, Kyung Ah Woo, Seong-Beom Koh, Kyum-Yil Kwon, Jangsup Mo
    Journal of Movement Disorders.2024; 17(1): 30.     CrossRef
  • Risk factors and intervention of caregiver burden in Parkinson’s disease: a systematic review and meta-analysis
    Yan Zhao, Wenxiang Wu, Jianjun Wu, Bin Shen, Yanpei Cao, Yafang Xu
    Quality of Life Research.2024;[Epub]     CrossRef
  • Impact of advanced Parkinson’s disease on caregivers: an international real-world study
    Pablo Martinez-Martin, Matej Skorvanek, Tove Henriksen, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Prasanna L. Kandukuri, Vivek S. Chaudhari, Apeksha B. Patel, Juan Carlos Parra, James Pike, Angelo Antonini
    Journal of Neurology.2023; 270(4): 2162.     CrossRef
  • Motor Complications and Treatment in Advanced Parkinson's Disease #456
    Caroline E. Olvera, Jori E. Fleisher, Neha M. Kramer
    Journal of Palliative Medicine.2023; 26(5): 730.     CrossRef
  • A single centre prospective study of three device-assisted therapies for Parkinson’s disease
    Hugo Morales-Briceño, Ainhi D. Ha, Han-Lin Chiang, Yicheng Tai, Florence C. F. Chang, David S. Tsui, Jane Griffith, Donna Galea, Samuel D. Kim, Belinda Cruse, Neil Mahant, Victor S. C. Fung
    npj Parkinson's Disease.2023;[Epub]     CrossRef
  • Unawareness of Apathy in Parkinson’s Disease: The Role of Executive Dysfunction on Symptom Recognition
    Gianpaolo Maggi, Carmine Vitale, Alessia Delle Curti, Marianna Amboni, Gabriella Santangelo
    Brain Sciences.2023; 13(6): 964.     CrossRef
  • Caregiver Burden in Late-Stage Parkinsonism and Its Associations
    Stefania Kalampokini, Adrianus L. A. J. Hommel, Stefan Lorenzl, Joaquim J. Ferreira, Wassilios G. Meissner, Per Odin, Bastiaan R. Bloem, Richard Dodel, Anette-Eleonore Schrag
    Journal of Geriatric Psychiatry and Neurology.2022; 35(1): 110.     CrossRef
  • Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries
    Angelo Antonini, Rajesh Pahwa, Per Odin, Tove Henriksen, Michael J. Soileau, Ramon Rodriguez-Cruz, Stuart H. Isaacson, Aristide Merola, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Juan Carlos Parra, Pavnit
    Neurology and Therapy.2022; 11(1): 303.     CrossRef
  • Impact of Isolation During the COVID-19 Pandemic on the Patient Burden of Parkinson’s Disease: A PMD Alliance Survey
    Neal Hermanowicz, Maria Cristina Ospina, Yasar Torres-Yaghi, Sherrie Gould, Kelly Papesh, Jason A Rivera, Susan Miller, Sarah Jones, Kelli Musick, Damian May
    Neuropsychiatric Disease and Treatment.2022; Volume 18: 633.     CrossRef
  • Exploring the experiences of living with Lewy body dementia: An integrative review
    Allison Bentley, Tessa Morgan, Yakubu Salifu, Catherine Walshe
    Journal of Advanced Nursing.2021; 77(12): 4632.     CrossRef
  • Neuropsychiatric symptoms in Parkinson’s disease: association with caregiver distress and disease severity
    Wan-Chen Tsai, Hui-Chen Lin, Chiung-Chih Chang, Wen-Neng Chang, Chih-Cheng Huang, Kuei-Yueh Cheng, Hung-Chen Wang, Wei-Che Lin, Sheng-Yuan Hsiao, Yun-Ru Lai, Cheng-Hsien Lu, Nai-Wen Tsai
    International Psychogeriatrics.2020; 32(6): 733.     CrossRef
  • Caregiver Burden, Quality of Life and Related Factors in Family Caregivers of Dementia Patients in Turkey
    Zeliha Tulek, Dilek Baykal, Sumeyye Erturk, Basar Bilgic, Hasmet Hanagasi, I. Hakan Gurvit
    Issues in Mental Health Nursing.2020; 41(8): 741.     CrossRef
  • Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
    Claudia Lazcano-Ocampo, Yi Min Wan, Daniel J van Wamelen, Lucia Batzu, Iro Boura, Nataliya Titova, Valentina Leta, Mubasher Qamar, Pablo Martinez-Martin, K Ray Chaudhuri
    Expert Review of Neurotherapeutics.2020; 20(5): 477.     CrossRef
  • A systematic review of the association between individual behavioural and psychological symptoms in dementia and carer burden
    Catriona George, Nuno Ferreira, Rosalind Evans, Victoria Honeyman
    Working with Older People.2020; 24(3): 181.     CrossRef
  • Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden


    Nicola Modugno, Angelo Antonini, Alessandro Tessitore, Pietro Marano, Francesco Ernesto Pontieri, Nicola Tambasco, Margherita Canesi, Giovanni Fabbrini, Mariachiara Sensi, Rocco Quatrale, Paolo Solla, Giovanni Defazio, Gabriella Melzi, Giuliana Gualberti,
    Neuropsychiatric Disease and Treatment.2020; Volume 16: 2899.     CrossRef
  • A Comparative Study of the Behavioral Profile of the Behavioral Variant of Frontotemporal Dementia and Parkinson’s Disease Dementia
    Dinesh Saini, Adreesh Mukherjee, Arijit Roy, Atanu Biswas
    Dementia and Geriatric Cognitive Disorders Extra.2020; 10(3): 182.     CrossRef
  • The long‐term direct and indirect economic burden among Parkinson's disease caregivers in the United States
    Pablo Martinez‐Martin, Dendy Macaulay, Yash J. Jalundhwala, Fan Mu, Erika Ohashi, Thomas Marshall, Kavita Sail
    Movement Disorders.2019; 34(2): 236.     CrossRef
  • The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress
    Toril Marie Terum, Ingelin Testad, Arvid Rongve, Dag Aarsland, Ellen Svendsboe, John Roger Andersen
    International Journal of Geriatric Psychiatry.2019; 34(10): 1421.     CrossRef
  • Trait Impulsivity Is Independent of Mild Cognitive Impairment in a Parkinson’s Disease Cohort
    Ashani Jeyadevan, Megan C. Bakeberg, Michelle Byrnes, Jade Kenna, Soumya Ghosh, Rick Stell, Sue Walters, Tess Evans, Sarah McGregor, Malcolm Horne, Frank L. Mastaglia, Ryan S. Anderton
    Parkinson's Disease.2019; 2019: 1.     CrossRef
  • Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study
    Alessandro Tessitore, Pietro Marano, Nicola Modugno, Francesco E. Pontieri, Nicola Tambasco, Margherita Canesi, Anna Latorre, Leonardo Lopiano, Mariachiara Sensi, Rocco Quatrale, Paolo Solla, Giovanni Defazio, Gabriella Melzi, Anna Maria Costanzo, Giulian
    Journal of Neurology.2018; 265(5): 1124.     CrossRef
  • Estudio observacional transversal de la sobrecarga en cuidadoras informales y los determinantes relacionados con la atención a las personas dependientes
    Ana María Rodríguez-González, Eva Rodríguez-Míguez, Ana Duarte-Pérez, Eduardo Díaz-Sanisidro, Ángel Barbosa-Álvarez, Ana Clavería
    Atención Primaria.2017; 49(3): 156.     CrossRef
  • Cognitive impairment in Parkinson's disease: impact on quality of life of carers
    RA Lawson, AJ Yarnall, F Johnston, GW Duncan, TK Khoo, D Collerton, JP Taylor, DJ Burn
    International Journal of Geriatric Psychiatry.2017; 32(12): 1362.     CrossRef
  • Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle
    Rita Moretti, Paola Caruso, Matteo Dal Ben
    Parkinson's Disease.2017; 2017: 1.     CrossRef
  • The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review
    Toril Marie Terum, John Roger Andersen, Arvid Rongve, Dag Aarsland, Ellen J. Svendsboe, Ingelin Testad
    International Journal of Geriatric Psychiatry.2017; 32(7): 703.     CrossRef
  • Neuropsychiatric symptoms in Alzheimer’s disease: associations with caregiver burden and treatment outcomes
    C.T. Chen, C.-C. Chang, W.-N. Chang, N.-W. Tsai, C.-C. Huang, Y.-T. Chang, H.-C. Wang, C.-T. Kung, Y.-J. Su, W.-C. Lin, B.-C. Cheng, C.-M. Su, S.-Y. Hsiao, C.-W. Hsu, C.-H. Lu
    QJM: An International Journal of Medicine.2017; 110(9): 565.     CrossRef
  • Hallucinations in Healthy Older Adults: An Overview of the Literature and Perspectives for Future Research
    Johanna C. Badcock, Hedwige Dehon, Frank Larøi
    Frontiers in Psychology.2017;[Epub]     CrossRef
  • Dementia Caregiver Burden: a Research Update and Critical Analysis
    Sheung-Tak Cheng
    Current Psychiatry Reports.2017;[Epub]     CrossRef
  • Patients and Their Caregivers’ Burdens for Parkinson’s Disease in Korea
    Jong Sam Baik, Joong-Seok Kim, Seong-Beom Koh, Jin Whan Cho, Phil Hyu Lee, Hyeo-Il Ma, Yun Joong Kim, Tae-Beom Ahn, Sang Jin Kim, Yong Duk Kim, Seong-min Choi, Ho-Won Lee, Hee Tae Kim
    Journal of Movement Disorders.2017; 10(3): 109.     CrossRef
  • Prevalence and treatment pattern of Parkinson's disease dementia in Korea
    Yoon‐Sang Oh, Joong‐Seok Kim, In‐Seok Park, Yong‐Soo Shim, In‐Uk Song, Jeong‐Wook Park, Phil‐Hyu Lee, Chul‐Hyung Lyoo, Tae‐Beom Ahn, Hyo‐Il Ma, Yong‐Duk Kim, Seong‐Beom Koh, Seung‐Jae Lee, Kwang‐Soo Lee
    Geriatrics & Gerontology International.2016; 16(2): 230.     CrossRef
  • Genetic architecture for human aggression: A study of gene–phenotype relationship in OMIM
    Yanli Zhang‐James, Stephen V. Faraone
    American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.2016; 171(5): 641.     CrossRef
  • The relationship between specific cognitive defects and burden of care in Parkinson's disease
    Michael Zhong, Richard Peppard, Dennis Velakoulis, Andrew H. Evans
    International Psychogeriatrics.2016; 28(2): 275.     CrossRef
  • Effect of lumbo-peritoneal shunt surgery on neuropsychiatric symptoms in patients with idiopathic normal pressure hydrocephalus
    Hideki Kanemoto, Hiroaki Kazui, Yukiko Suzuki, Syunsuke Sato, Haruhiko Kishima, Toshiki Yoshimine, Kenji Yoshiyama
    Journal of the Neurological Sciences.2016; 361: 206.     CrossRef
  • The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease
    Stefan Hermanowicz, Neal Hermanowicz
    Expert Review of Neurotherapeutics.2016; 16(6): 625.     CrossRef
  • Neuropsychiatric symptoms in Serbian patients with Parkinson's disease
    Mirjana Petrovic, Elka Stefanova, Ljubomir Ziropadja, Tanja Stojkovic, Vladimir S. Kostic
    Journal of the Neurological Sciences.2016; 367: 342.     CrossRef
  • Managing cognition in progressive supranuclear palsy
    Timothy Rittman, Ian TS Coyle-Gilchrist, James B Rowe
    Neurodegenerative Disease Management.2016; 6(6): 499.     CrossRef
Review Article
New Perspective on Parkinsonism in Frontotemporal Lobar Degeneration
Hee Kyung Park, Sun J. Chung
J Mov Disord. 2013;6(1):1-8.
DOI: https://doi.org/10.14802/jmd.13001
  • 24,413 View
  • 238 Download
  • 25 Crossref
AbstractAbstract PDF

Frontotemporal dementia (FTD) is the second most common type of presenile dementia. Three clinical prototypes have been defined; behavioral variant FTD, semantic dementia, and progressive nonfluent aphasia. Progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease may possess clinical and pathological characteristics that overlap with FTD, and it is possible that they may all belong to the same clinicopathological spectrum. Frontotemporal lobar degeneration (FTLD) is a clinicopathological syndrome that encompasses a heterogenous group of neurodegenerative disorders. Owing to the advancement in the field of molecular genetics, diagnostic imaging, and pathology, FTLD has been the focus of great interest. Nevertheless, parkinsonism in FTLD has received relatively less attention. Parkinsonism is found in approximately 20–30% of patients in FTLD. Furthermore, parkinsonism can be seen in all FTLD subtypes, and some patients with familial and sporadic FTLD can present with prominent parkinsonism. Therefore, there is a need to understand parkinsonism in FTLD in order to obtain a better understanding of the disease. With regard to the clinical characteristics, the akinetic rigid type of parkinsonism has predominantly been described. Parkinsonism is frequently observed in familial FTD, more specifically, in FTD with parkinsonism linked to chromosome 17q (FTDP-17). The genes associated with parkinsonism are microtubule associated protein tau (MAPT), progranulin (GRN or PGRN), and chromosome 9 open reading frame 72 (C9ORF72) repeat expansion. The neural substrate of parkinsonism remains to be unveiled. Dopamine transporter (DAT) imaging revealed decreased uptake of DAT, and imaging findings indicated atrophic changes of the basal ganglia. Parkinsonism can be an important feature in FTLD and, therefore, increased attention is needed on the subject.

Citations

Citations to this article as recorded by  
  • Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
    Harry Costello, Jonathan P. Roiser, Robert Howard
    Psychological Medicine.2023; 53(3): 654.     CrossRef
  • Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
    Luigi Fiondella, Priya Gami-Patel, Christian A. Blok, Annemieke J. M. Rozemuller, Jeroen J. M. Hoozemans, Yolande A. L. Pijnenburg, Marta Scarioni, Anke A. Dijkstra
    Acta Neuropathologica Communications.2023;[Epub]     CrossRef
  • Demencias degenerativas: ¿un dilema de síndromes o de enfermedades?
    A. Robles Bayón
    Neurología.2022; 37(6): 480.     CrossRef
  • Degenerative dementias: a question of syndrome or disease?
    A. Robles Bayón
    Neurología (English Edition).2022; 37(6): 480.     CrossRef
  • Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration—Insights into disease mechanisms and current therapeutic approaches
    Nadine Huber, Sonja Korhonen, Dorit Hoffmann, Stina Leskelä, Hannah Rostalski, Anne M. Remes, Paavo Honkakoski, Eino Solje, Annakaisa Haapasalo
    Molecular Psychiatry.2022; 27(3): 1300.     CrossRef
  • Novel frameshift CTSF mutation causing kufs disease type B mimicking frontotemporal dementia-parkinsonism
    Murat Gultekin, Zeynep Tufekcioglu, Recep Baydemir
    Neurocase.2022; 28(1): 107.     CrossRef
  • Dopamine Transporter Imaging for Frontotemporal Lobar Degeneration With Motor Neuron Disease
    Ryota Kobayashi, Shinobu Kawakatsu, Makoto Ohba, Daichi Morioka, Masafumi Kanoto, Koichi Otani
    Frontiers in Neuroscience.2022;[Epub]     CrossRef
  • Investigational therapeutics for the treatment of progressive supranuclear palsy
    David G Coughlin, Irene Litvan
    Expert Opinion on Investigational Drugs.2022; 31(8): 813.     CrossRef
  • Frequency and Longitudinal Course of Motor Signs in Genetic Frontotemporal Dementia
    Sonja Schönecker, Francisco J. Martinez-Murcia, Boris-Stephan Rauchmann, Nicolai Franzmeier, Catharina Prix, Elisabeth Wlasich, Sandra V. Loosli, Katja Bochmann, Juan-Manuel Gorriz Saez, Robert Laforce, Simon Ducharme, Maria Carmela Tartaglia, Elizabeth F
    Neurology.2022;[Epub]     CrossRef
  • Multi-Modal Synergistic 99mTc-TRODAT-1 SPECT and MRI for Evaluation of the Efficacy of Hyperbaric Oxygen Therapy in CO-Induced Delayed Parkinsonian and Non-Parkinsonian Syndromes
    Skye Hsin-Hsien Yeh, Chuang-Hsin Chiu, Hung-Wen Kao, Ching-Po Lin, Yu-Hus Lai, Wen-Sheng Huang
    Antioxidants.2022; 11(11): 2289.     CrossRef
  • Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia
    Jun Yup Lee, Oana C. Marian, Anthony S. Don
    NeuroMolecular Medicine.2021; 23(1): 1.     CrossRef
  • Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases
    Daisy Sproviero, Stella Gagliardi, Susanna Zucca, Maddalena Arigoni, Marta Giannini, Maria Garofalo, Martina Olivero, Michela Dell’Orco, Orietta Pansarasa, Stefano Bernuzzi, Micol Avenali, Matteo Cotta Ramusino, Luca Diamanti, Brigida Minafra, Giulia Peri
    International Journal of Molecular Sciences.2021; 22(5): 2737.     CrossRef
  • Parkin beyond Parkinson’s Disease—A Functional Meaning of Parkin Downregulation in TDP-43 Proteinopathies
    Katarzyna Gaweda-Walerych, Emilia Jadwiga Sitek, Ewa Narożańska, Emanuele Buratti
    Cells.2021; 10(12): 3389.     CrossRef
  • Joint contractures and acquired deforming hypertonia in older people: Which determinants?
    Patrick Dehail, Nathaly Gaudreault, Haodong Zhou, Véronique Cressot, Anne Martineau, Julie Kirouac-Laplante, Guy Trudel
    Annals of Physical and Rehabilitation Medicine.2019; 62(6): 435.     CrossRef
  • Review: Clinical, genetic and neuroimaging features of frontotemporal dementia
    R. Convery, S. Mead, J. D. Rohrer
    Neuropathology and Applied Neurobiology.2019; 45(1): 6.     CrossRef
  • Granulin in Frontotemporal Lobar Degeneration: Molecular Mechanisms of the Disease
    Zemfira N. Karamysheva, Elena B. Tikhonova, Andrey L. Karamyshev
    Frontiers in Neuroscience.2019;[Epub]     CrossRef
  • The Whole Exome Sequencing Clarifies the Genotype- Phenotype Correlations in Patients with Early-Onset Dementia
    Yangqi Xu, Xiaoli Liu, Junyi Shen, Wotu Tian, Rong Fang, Binyin Li, Jianfang Ma, Li Cao, Shengdi Chen, Guanjun Li, Huidong Tang
    Aging and disease.2018; 9(4): 696.     CrossRef
  • Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology
    Rebekah M. Ahmed, Muireann Irish, Janet van Eersel, Arne Ittner, Yazi D. Ke, Alexander Volkerling, Julia van der Hoven, Kimi Tanaka, Tim Karl, Michael Kassiou, Jillian J. Kril, Olivier Piguet, Jürgen Götz, Matthew C. Kiernan, Glenda M. Halliday, John R. H
    Neuroscience & Biobehavioral Reviews.2017; 74: 126.     CrossRef
  • Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases
    Anne-Claire Dupont, Bérenger Largeau, Maria Santiago Ribeiro, Denis Guilloteau, Claire Tronel, Nicolas Arlicot
    International Journal of Molecular Sciences.2017; 18(4): 785.     CrossRef
  • Intrinsic functional connectivity alterations in progressive supranuclear palsy: Differential effects in frontal cortex, motor, and midbrain networks
    Johannes Rosskopf, Martin Gorges, Hans‐Peter Müller, Dorothée Lulé, Ingo Uttner, Albert C. Ludolph, Elmar Pinkhardt, Freimut D. Juengling, Jan Kassubek
    Movement Disorders.2017; 32(7): 1006.     CrossRef
  • Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred
    Gianluca Floris, Giuseppe Borghero, Francesca Di Stefano, Rosanna Melis, Roberta Puddu, Laura Fadda, Maria R. Murru, Daniela Corongiu, Stefania Cuccu, Stefania Tranquilli, Antonino Cannas, Maria G. Marrosu, Adriano Chiò, Francesco Marrosu
    Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2016; 17(3-4): 245.     CrossRef
  • Clinical features ofTBK1carriers compared withC9orf72,GRNand non-mutation carriers in a Belgian cohort
    Sara Van Mossevelde, Julie van der Zee, Ilse Gijselinck, Sebastiaan Engelborghs, Anne Sieben, Tim Van Langenhove, Jan De Bleecker, Jonathan Baets, Mathieu Vandenbulcke, Koen Van Laere, Sarah Ceyssens, Marleen Van den Broeck, Karin Peeters, Maria Mattheijs
    Brain.2016; 139(2): 452.     CrossRef
  • Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis
    Carmen Gasca-Salas, Mario Masellis, Edwin Khoo, Binit B. Shah, David Fisman, Anthony E. Lang, Galit Kleiner-Fisman, Patrick Lewis
    PLOS ONE.2016; 11(4): e0153852.     CrossRef
  • The clinical spectrum of sporadic and familial forms of frontotemporal dementia
    Ione O. C. Woollacott, Jonathan D. Rohrer
    Journal of Neurochemistry.2016; 138(S1): 6.     CrossRef
  • Genetics of Progressive Supranuclear Palsy
    Sun Young Im, Young Eun Kim, Yun Joong Kim
    Journal of Movement Disorders.2015; 8(3): 122.     CrossRef
Case Reports
A Case of Multiple System Atrophy-Cerebellar Type Preceded by Dementia
Eun Hye Jang, Joo Kyung Lee, Hyun Jung Jang, Mi-Jung Kim, Sun Ju Chung
J Mov Disord. 2012;5(2):48-52.
DOI: https://doi.org/10.14802/jmd.12011
  • 16,655 View
  • 92 Download
  • 3 Crossref
AbstractAbstract PDF

Multiple system atrophy (MSA) is a sporadic, adult-onset disease characterized by progressive degeneration of nervous systems including cerebellar, pyramidal, extrapyramidal, and autonomic system. Although a few recent studies reported that cognitive impairments could occur in patients with MSA, prominent dementia with progressive decline is not a typical clinical manifestation of MSA. In particular, dementia with MSA-cerebellar type is very rare. We have experienced a patient with 2-year history of severe cognitive impairment, who was finally diagnosed as MSA-cerebellar type.

Citations

Citations to this article as recorded by  
  • Mitochondrial dysfunction and altered ribostasis in hippocampal neurons with cytoplasmic inclusions of multiple system atrophy
    Norihisa Maeda, Hiroyuki Honda, Satoshi O. Suzuki, Naoki Fujii, Jun‐ichi Kira, Toru Iwaki
    Neuropathology.2018; 38(4): 361.     CrossRef
  • Mechanisms and prevention of sudden death in multiple system atrophy
    Takayoshi Shimohata, Naotaka Aizawa, Hideaki Nakayama, Hiroshige Taniguchi, Yasuyoshi Ohshima, Hitoshi Okumura, Tetsuya Takahashi, Akio Yokoseki, Makoto Inoue, Masatoyo Nishizawa
    Parkinsonism & Related Disorders.2016;[Epub]     CrossRef
  • Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders
    Erin E. Robertson, Deborah A. Hall, Andrew R. McAsey, Joan A. O’Keefe
    The Clinical Neuropsychologist.2016; 30(6): 849.     CrossRef
Levodopa-Induced Facial Dystonia in a Case of Progressive Supranuclear Palsy
Eun Joo Chung, Sang Jin Kim
J Mov Disord. 2012;5(1):28-32.
DOI: https://doi.org/10.14802/jmd.12008
  • 17,030 View
  • 67 Download
  • 4 Crossref
AbstractAbstract PDF

Progressive supranuclear palsy (PSP) is frequently misdiagnosed as other Parkinsonism because of clinical heterogeneity of PSP. We present here a case of a 67-year-old male patient with frontotemporal dementia-like cognitive impairment including language difficulties and abnormal behaviors. He showed severe facial dystonia after the levodopa treatment. Herein, we describe an unusual case of a patient presenting with PSP which, we believe could contribute to our knowledge about atypical leveodopa-induced facial dystonia in PSP.

Citations

Citations to this article as recorded by  
  • Use of botulinum toxin in the management of dystonia in Parkinson’s disease
    Charenya Anandan, Joseph Jankovic
    Frontiers in Neuroscience.2024;[Epub]     CrossRef
  • Lower Cranial Dystonia with Inflated Cheeks: A Case of Dystonic Respiratory Failure
    Takashi Suzuki, Takao Makifuchi, Nobuyoshi Fukuhara
    Internal Medicine.2023; 62(11): 1671.     CrossRef
  • Dystonia in atypical parkinsonian disorders
    Luca Marsili, Matteo Bologna, Maja Kojovic, Alfredo Berardelli, Alberto J. Espay, Carlo Colosimo
    Parkinsonism & Related Disorders.2019; 66: 25.     CrossRef
  • A Review of Treatment Options for Progressive Supranuclear Palsy
    Maria Stamelou, Günter Höglinger
    CNS Drugs.2016; 30(7): 629.     CrossRef
Review Articles
Clinicopathological Correlates of Lewy Body Disease: Fundamental Issues
Tae-Beom Ahn
J Mov Disord. 2010;3(1):11-14.
DOI: https://doi.org/10.14802/jmd.10003
  • 10,518 View
  • 62 Download
  • 3 Crossref
AbstractAbstract PDF

Lewy body pathology (LBP) is the pathological hallmark of Lewy body diseases, such as Parkinson’s disease and Lewy body dementia. Recent studies have shed new light on the role of LBP, the interactions of LBP with concomitant pathologies, and the propagation of LBP from the olfactory bulb and enteric nervous system to the central nervous system. The intrinsic difficulty with identifying clinicopathological correlates could be overcome by improving our understanding of the pathological evolution of LBP.

Citations

Citations to this article as recorded by  
  • Demencias degenerativas: ¿un dilema de síndromes o de enfermedades?
    A. Robles Bayón
    Neurología.2022; 37(6): 480.     CrossRef
  • Degenerative dementias: a question of syndrome or disease?
    A. Robles Bayón
    Neurología (English Edition).2022; 37(6): 480.     CrossRef
  • Advances in NURR1-Regulated Neuroinflammation Associated with Parkinson’s Disease
    Murad Al-Nusaif, Yushan Lin, Tianbai Li, Cheng Cheng, Weidong Le
    International Journal of Molecular Sciences.2022; 23(24): 16184.     CrossRef
Comparing Cerebral White Matter Lesion Burdens between Parkinson’s Disease with and without Dementia
Sun-Ah Choi, Virgilio Gerald H. Evidente, John N Caviness
J Mov Disord. 2010;3(1):6-10.
DOI: https://doi.org/10.14802/jmd.10002
  • 18,895 View
  • 72 Download
  • 3 Crossref
AbstractAbstract PDF

Cerebral white matter lesions (CWMLs) have been suggested to be associated with an increased risk of dementia, disability, and death. CWMLs are more common in individuals with Alzheimer’s disease (AD) than in normal elderly individuals of comparable age. Only a few studies have been done to determine whether CWMLs may influence cognitive decline in Parkinson’s disease (PD). Fully developed PD with concurrent AD was reported to likely cause impaired cognition in spite of accumulating evidence suggesting that PD with dementia (PDD) is more closely associated with Lewy body (LB) pathology. Currently, contradictory data on the neuropathology of dementia in PD require further prospective clinicopathological studies in larger cohorts to elucidate the impact of AD and α-synuclein (SCNA) pathologies on the cognitive status in these disorders. Previous reports did not suggest CWMLs to be associated with an increased risk of PDD. After adjusting for age at death, age at onset of PD, and duration of PD, our recent study investigating CWMLs in PDD via autopsy has shown a positive correlation between the burden of CWMLs and PDD. The frequent co-existence of both LB and AD lesions suggests that both pathologies independently or synergistically contribute to both movement disorders and cognitive impairment. The individual and cumulative burden of CWMLs, LB lesions, and AD lesions may synergistically contribute to cognitive decline in LB disorders such as PDD.

Citations

Citations to this article as recorded by  
  • Cx43 Mediates Resistance against MPP+-Induced Apoptosis in SH-SY5Y Neuroblastoma Cells via Modulating the Mitochondrial Apoptosis Pathway
    In-Su Kim, Palanivel Ganesan, Dong-Kug Choi
    International Journal of Molecular Sciences.2016; 17(11): 1819.     CrossRef
  • Gray and White Matter Contributions to Cognitive Frontostriatal Deficits in Non-Demented Parkinson's Disease
    Catherine C. Price, Jared Tanner, Peter T. Nguyen, Nadine A. Schwab, Sandra Mitchell, Elizabeth Slonena, Babette Brumback, Michael S. Okun, Thomas H. Mareci, Dawn Bowers, Stephen D Ginsberg
    PLOS ONE.2016; 11(1): e0147332.     CrossRef
  • White Matter Hypoperfusion and Damage in Dementia: Post‐Mortem Assessment
    Seth Love, J Scott Miners
    Brain Pathology.2015; 25(1): 99.     CrossRef
Original Article
Mild Cognitive Impairment in Parkinson’s Disease
Jae Woo Kim, Hee Young Jo, Min Jeong Park, Sang-Myung Cheon
J Mov Disord. 2008;1(1):19-25.
DOI: https://doi.org/10.14802/jmd.08004
  • 9,410 View
  • 94 Download
  • 8 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Background

To determine the frequency of mild cognitive impairment (MCI) of Parkinson’s disease (PD, PDMCI) and its subtypes among non-demented PD patients, and to identify the influence of the age and presenting symptom on the development of PDMCI.

Methods:

A total 141 non-demented PD patients underwent a comprehensive neuropsychological assessment including attention, language, visuospatial, memory and frontal functions. PDMCI was defined by neuropsychological testing and was classified into five subtypes. Patients were divided into two groups (tremor vs. akinetic-rigid type) for presenting symptom and three groups according to the age. Neuropsychological performance of patients was compared with normative data.

Results:

Almost half (49.6%) of non-demented PD patients had impairment in at least one domain and can be considered as having PDMCI. Executive type of PDMCI was the most frequent and amnestic, visuospatial, linguistic and attention types followed in the order of frequency. The population of PDMCI was increasing as the age of disease onset was higher. Whereas the frequency of executive and amnestic types of PDMCI was comparable in younger group, executive type was the most frequent in older group. The patients with tremor dominant type performed worse on tests, particularly on attention test.

Conclusions:

MCI was common even in the early stage of PD and the subtype was diverse. Unlike MCI developing Alzheimer’s disease later, executive type of PDMCI was the most common. Age was an important risk factor for development of MCI in PD. The concept of MCI should be introduced in PD.

Citations

Citations to this article as recorded by  
  • Orthostatic Hypotension and Cognitive Impairment in <i>De Novo</i> Patients with Parkinson’s Disease
    Hyo-Jin Bae, Jun-Ho Lim, Sang-Myung Cheon
    Journal of Movement Disorders.2014; 7(2): 102.     CrossRef
  • Correlated regions of cerebral blood flow with clinical parameters in Parkinson’s disease; comparison using ‘Anatomy’ and ‘Talairach Daemon’ software
    Hyun Jin Yoon, Sang Myung Cheon, Young Jin Jeong, Do-Young Kang
    Annals of Nuclear Medicine.2012; 26(2): 164.     CrossRef
  • Correlation between neuropsychological tests and hypoperfusion in MCI patients: anatomical labeling using xjView and Talairach Daemon Software
    Hyun Jin Yoon, Kyung Won Park, Young Jin Jeong, Do-Young Kang
    Annals of Nuclear Medicine.2012; 26(8): 656.     CrossRef
  • Significant correlation between cerebral hypoperfusion and neuropsychological assessment scores of patients with mild cognitive impairment
    Hyun Jin Yoon, Kyung Won Park, Young Jin Jeong, Do-Young Kang
    Nuclear Medicine Communications.2012; 33(8): 848.     CrossRef
  • Utility and Limitations of Addenbrooke’s Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinson’s Disease
    Natalie C. Komadina, Zoe Terpening, Yue Huang, Glenda M. Halliday, Sharon L. Naismith, Simon J.G. Lewis
    Dementia and Geriatric Cognitive Disorders.2011; 31(5): 349.     CrossRef
  • Characterizing mild cognitive impairment in Parkinson's disease
    John C. Dalrymple‐Alford, Leslie Livingston, Michael R. MacAskill, Charlotte Graham, Tracy R. Melzer, Richard J. Porter, Richard Watts, Tim J. Anderson
    Movement Disorders.2011; 26(4): 629.     CrossRef

JMD : Journal of Movement Disorders Twitter